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ABSTRACT

Loss of a leg or arm is a tremendous disability. Immediate and obvious
impairments are decreased mobility or diminished functional capacity. Not quite as
obvious are the difficulties associated with activities of daily living, quality of life
impairments, sometimes loss of independence or employment, and the mental
health issues which often accompany limb loss. The interface between native tissue
and the prosthetic limb presents the greatest challenge to amputee rehabilitation.
Computer-controlled robotic limbs have been widely available since the 1990s.
However, the weight of prosthetic limbs, coupled with the difficulty of where to locate
the components, requires substantial loads to be transferred through the humanimplant interface. This interface has always been a skin-squeezing mechanism
which results in repetitive soft-tissue loading and trauma, in both compression and
shear, which inevitably causes multiple problems (pain, skin breakdown and
infection, hyperhidrosis, allergic reaction to the material) leading to periodic or
prolonged prosthesis disuse. So unfortunately, despite all the effort and expense
invested in the prosthetic limb itself, patients often were unable to benefit.
Percutaneous EndoProsthetic Osseointegration for Limbs (PEPOL) is a
revolutionary technique that involves anchoring a metal implant directly to a patient’s
skeleton, then permanently passed through the patient’s skin, and attached to a
prosthetic limb. By doing this, the weight of the prosthesis is borne by the patient’s
skeleton and is directly powered by muscles, leading to a lighter and more native
experience. The skin is no longer compressed and traumatised, eliminating the
aforementioned issues. Since learning about this technology in the mid-2000s and
performing my first independent procedure in 2009, I have investigated and
pioneered the world’s leading surgical techniques and rehabilitative methods for
PEPOL. Treating nearly 1000 amputees via the Osseointegration Group of Australia
and the MQ Health Limb Reconstruction Centre at Macquarie University has allowed
research to be performed on this technology, documented, and discussed in the
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Body of Work. Patients almost always improve their objective and assessed mobility
performance (Overall 38.6% distance improvement on the 6MWT), they wear their
prosthetic limb more (Overall 38.1% increase in the Q-TFA Prosthetic Use Score),
and they are subjectively more satisfied with their condition as an amputee (Overall
41.1% increase in the Q-TFA Global Score) . While these benefits are consistent, my
research has also identified the fortunately limited problems with infection and soft
tissue management (29% of all patients required re-operations due to direct or
indirect complications). PEPOL clearly provides excellent improvement for the vast
majority of patients, and the continued investigation of this technology should lead to
even greater improvements in progressing from what is already successful, make it
more readily available, and ameliorate its existing challenges.
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THE ORIGINS OF OSSEOINTEGRATION FOR AMPUTEES
Introduction

Humans have innovated replacements for amputated body parts for centuries.
The oldest currently known prosthesis is a great toe found on an Egyptian mummy in
a Thebes-West necropolis, dated to 1550-700 BC (Figure 1)1. While this toe likely
was of relatively low functional demand, Roman general Marcus Sergius led charges
in multiple campaigns using an iron right hand and shield prosthesis during the
Second Punic War (218-201 BC)2. Detailed prosthetic drawings by Ambroise Paré3
reveal that fundamental interface designs have not substantially changed since the
1500s: a replacement body part is attached to the remaining limb by compressing
and adhering to the skin and being suspended from the soft tissues (Figure 2)4.
Despite possibly romanticized notions of prosthesis performance in history, today’s
prosthesis users know many serious challenges significantly diminish their quality of
life with traditional skin-suspended solutions. Challenges related to prosthetics can
be briefly summarized to include the following: dermatologic problems causing
intermittent prosthesis disuse in at least 15-41% of patients5; on average, nine
prosthetist clinical service visits are needed annually6; a new socket is required at
least every other year7–9; one in three patients may not regain employment10; and an
estimated 25% of these patients struggle to walk 500 metres11.
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Figure 1. Oldest known prosthesis.
Right great toe found on mummy from Thebes-West. A) side view of the preserved foot shows the
great toe was amputated while the patient was alive, as skin (now preserved) had healed over the
amputation. B) A wooden prosthesis is strapped to the forefoot by a fabric lace. C) Plantar surface of
prosthesis shows abrasion, indicating use while alive. D) Radiograph showing healing bone response
of the first metatarsal indicating long term survival of the patient following amputation. Reproduced
with permission from Nerlich AG, Zink A, Szeimies U, Hagedorn HG. Ancient Egyptian prosthesis of
the big toe. The Lancet. 2000 Dec 23;356(9248):2176-9.
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Figure 2. Two drawings from barber/surgeon Ambroise Paré.
The top drawing of the "iron hand" shows mechanisms to move the fingers. The bottom drawing
shows buckle straps are used to suspend the hand by squeezing the residual forearm skin.
Reproduced with permission courtesy of the National Library of Medicine. Paré, Ambroise. [Les
Oeuvres]. page 916. A Paris: Chez Gabriel Buon, 1585.
https://www.nlm.nih.gov/exhibition/historicalanatomies/Images/1200_pixels/ixcxvi.jpg accessed 7 Feb
2020.

In 1990, a critical technical achievement occurred. The first long-term durable
bone-anchored prosthesis was successfully implanted into a femoral amputee. This
proof-of-concept allowed fundamental changes in human-prosthesis interfacing to
occur which led to a paradigm shift in rehabilitation care for amputees. First, having a
bone-metal-prosthesis linkage permitted nearly lossless energy transfer from person
to prosthesis. Second, the skin of a person’s extremity was no longer subject to
constant pathologic compression. These key principles facilitated prosthesis designs
which routinely result in better quality of life for most amputees12. The following
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sections present a concise history of PEPOL, how it is both similar to and different
from its slightly older cousin dental osseointegration (DOI) and discuss the currently
relevant PEPOL implants.

History

The term “osseointegration” is defined as the phenomenon of bone growing
directly onto and attaching to the surface of a material without an intermediate layer
such as fibrous tissue. This process was formally recognized by Dr. Per-Ingvar
Brånemark. As early as 195213, while performing studies investigating blood
circulation, his team serendipitously discovered that titanium implants screwed into
rabbit bone bonded tightly and without a fibrous tissue layer14. Titanium was a
material of recent medical interest, with other researchers identifying there was no
inflammatory response elicited from dog muscle just a few years earlier15. By 1965,
following a series of experiments on dogs13, Dr. Brånemark became the first to use
titanium as a long term implant into human bone, specifically dental implants (Figure
3)16,17, and by 1977 formally documented the term “osseointegration18,19.” The impact
of DOI is unquestionable: a PubMed search for “Brånemark” produces hundreds of
articles describing dental implants and the Brånemark System is a registered
commercial dental implant20. Per-Ingvar’s son, Rickard Brånemark, performed the
first long-term successful PEPOL on 15 May 199021 for a 25-year-old woman who
had lost both her legs 10 years prior due to a tram accident. The following year she
had the other leg treated in the same manner (Figure 4). This progression of PEPOL
from DOI was important, because even though DOI had been successful for almost
thirty years, other surgeons had tried and failed with PEPOL.
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Figure 3. Brånemark style dental osseointegration.
A) Schematic showing titanium implant with a screw fixation design. There are three components of
this style of implant: 1, titanium post that achieves osseointegration with the jaw; 2, abutment which
screws into the post and remains smooth and motionless at the gingiva; and 3, the crown which is
designed to match the patient’s tooth. B) The design is modular with the post separate from the
crown. C and D) Single and multiple crown prostheses attached to an osseointegrated post. Figures
adapted with permission from Adell R, Lekholm U, Rockler BR, Brånemark PI. A 15-year study of
osseointegrated implants in the treatment of the edentulous jaw. International journal of oral surgery.
1981 Jan 1;10(6):387-416.

Figure 4. Photograph of the first patient with long term successful osseointegration.
Figure adapted with permission from Li Y, Brånemark R. Osseointegrated prostheses for rehabilitation
following amputation. Der Unfallchirurg. 2017 Apr 1;120(4):285-92.
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The first documented repetitively successful implementation of a
transcutaneous orthopedic device may have been Joseph-François Malgaigne’s
double sided hook. Designed in 1840, the construct featured a double hook design at
each end which penetrated the patient’s skin and clamped the superior and inferior
poles of the patella, providing compression forces to reduce a fracture (Figure 5).
Soon after, he also innovated on an early type of external fixation device22,23 though
more recognizable external fixation instrumentation was described by Codivilla and
Steinmann between 1903 and 191024–28. One specific insight Malgaigne had was
particularly ahead of his time: redness, necrosis, and other signs of inflammation did
not occur so long as the hooks did not slip and skin motion was eliminated.

Figure 5. Double sided metal clamp designed by Joseph-François Malgaigne in 1840.
This is the first documented repetitively successful transcutaneous orthopaedic device.

The history of early osseointegration can be pieced together thanks to Hulbert
et al29 and Murphy30 in the 1970s, with recent developments being outlined by
Webster et al31. The first documented skeletally linked transcutaneous prosthetic
attempts were likely the pilot studies performed by Dr. Elliott Culter and Dr. James
Blodgett as early as 1942 at Harvard University sponsored by the United States
Office of Scientific Research and Development. Those surgeons tested stainless
steel and Vitallium screws inserted into the intramedullary canal of 18 dogs (Figure
6). Vitallium retained stability better and the researchers determined that the implant
must remain motionless relative to the bone to prevent loosening. Along with Dr. Tait
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Chisholm, they also implanted a Vitallium screw-style anchored tooth in a dog30,32.
By 1949, the United States Veterans Administration felt the surgical challenges for
success in humans were too great and suspended further investigation.

Figure 6 Schematic of osseointegration implant used experimentally in dogs.
This was by Dr. Elliott Culter and Dr. James Blodgett in the 1940s.
The retention is achieved by a screw design. The dotted lines identify the portion of the implant that
had worn away with prolonged use. Reproduced with permission from Murphy EF. History and
philosophy of attachment of prostheses to the musculo-skeletal system and of passage through the
skin with inert materials. Journal of biomedical materials research. 1973 May;7(3):275-95.

The first attempt to replace an amputated limb with a skeletally anchored
prosthesis in a human appears to have been Dr. G. Dümmer in 194630. He treated
four transtibial amputees with a stainless steel intramedullary implant which featured
a cross-screw for maintaining position (Figure 7). These implants were removed after
an unspecified but apparently short period of time, possibly due to infection, and
perhaps even before obvious signs of failure presented. During 1956-1969, with
renewed interest from the United States Veterans Administration (VA), Dr. John
Esslinger began a series of experiments with dogs and a monkey aimed at
evaluating how to overcome two challenges: 1) a stable and healthy skin-implant
interface, and 2) a reliable, stable integration of implant to skeleton. He
experimented with stainless steel, titanium, Teflon, and rubber implants, preferring a
two-stage technique. The first stage was to insert an implant and then close the
14

wound to allow the bone to integrate with the implant, followed by a second
procedure to insert a transcutaneous connector to attach a prosthesis. He found that
a Teflon intramedullary implant with a mushroom shaped cap over the distal bone
end prevented bone overgrowth and seemed the most successful over several
years. However, all options eventually failed and had to be removed. His report was
more observational than mechanistically driven and did not feature histologic
descriptions, tables of results, or any figures demonstrating these novel
techniques33.

Figure 7 Schematic of first skeletally implanted transcutaneous prosthetic anchor documented to be
used in a human, designed by Dr. G. Dümmer in 1946.
The retention mechanism was the two cross-pins through the bone and implant. Reproduced with
permission from Murphy EF. History and philosophy of attachment of prostheses to the musculo‐
skeletal system and of passage through the skin with inert materials. Journal of biomedical materials
research. 1973 May;7(3):275-95.

In 1967, Dr. Charles William Hall and his team, also working with the VA,
described using stainless steel intramedullary implants in dogs and even connected
the remnant muscles of the amputated limbs to articulating distal joints with artificial
tendons (Figure 8)34,35. Feeling optimistic, in 1974 they wrote “a permanently
attached artificial limb is an achievable dream within the foreseeable future. The
problems remaining to be solved are the interfaces which need to be maintained
between the prosthetic device and bone, and between the prosthesis and the skin
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through which it protrudes36.” In 1967 Dr. Vert Mooney, working at the rehabilitation
center Rancho Los Amigos, tried using a porous ceramic in a patient’s humerus
which became loose and infected by around 8 months (Figure 9)37. One issue
identified was the deeper the grooves of the implant, the longer the intraosseous
vascular channels had to be to metabolically support the interdigitating bone.
Recognizing the success of using polymethylmethacrylate (PMMA, bone cement) for
total hip replacements38, Dr. Mooney attempted cementing an implant into three
patients. These uniformly also became loose and required removal within a year
(Figure 10)39. Titanium was considered a good candidate because it formed a stable
protective oxide, was reasonably closer modulus of elasticity to bone, had the
mechanical working advantages of metal, and developed bonding to bone without
inciting an inflammatory response either in bone or soft tissue15,40. Rapid and
excellent integration was proven by inserting titanium blocks with sintered threads in
rabbits and dogs: no foreign body reactions occurred, and maximum pull-out
strength was achieved by 2 weeks41.
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Figure 8. Osseointegration implant experimental devices used by Dr. Charles W. Hall in the 1960s.
A) Some designs aimed to allow remnant muscle to power external prosthetic joints by sewing an
artificial tendon to the muscle and passing it through the skin and attaching it in a way that mimicked
native attachment locations. B) Schematic of early bone anchored prosthesis designs. The material
was stainless-steel. A unique feature is the implant clamped onto the external surface of the bone
rather than fitting into the intramedullary canal, as Dr. Hall's group believed the vascular supply would
be better. Reproduced with permission from Hall CW, Cox PA, Mallow WA. Skeletal extension
development: criteria for future designs. Bull Prosthet Res. 1976 Spring;(10-25):69-96.
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Figure 9. Cerosium implant used by Dr. Vert Mooney in 1967.
A) Radiograph and B) clinical photo of patient with a right humerus implant. Figures adapted with
permission from Mooney V, Predecki PK, Renning J, Gray J. Skeletal extension of limb prosthetic
attachments–Problems in tissue reaction. Journal of Biomedical Materials Research. 1971
Nov;5(6):143-59.

Figure 10. Early attempts of cementing a stainless-steel implant.
A) Stainless-steel implant B) cemented into trans-humeral amputees in the 1970s using a cement
retention strategy. Adapted with permission from Mooney, V., Schwartz, S.A., Roth, A.M. et al. Ann
Biomed Eng (1977) 5: 34.

Despite DOI being increasingly used with consistent success and the routine
integration of bone into enclosed titanium implants, Dr. Hall lamented “years of
experimental frustration have led investigators to accept the fact that penetration of
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the skin at the end of the amputated stump will always fail because prevalent biaxial
stresses tend to enlarge the exit site and tear the interfacial bond42.” This was written
in 1985, in what appears to be his final article and culmination of his two decades of
work dedicated to this endeavour43. The final material they reported using was a
titanium alloy (Ti6Al4Va). This is essentially the same as is used in current implants,
and identical to the implant used by Dr. Richard Brånemark just five years later
which resulted in more than twenty years of patient mobility. It appears that in their
focus to establish a tight skin seal, Dr. Hall’s team as well as most others before
them had experimented with various polymers and fabrics attempting to get the skin
to stabilize around, grow into, or otherwise form an impermeable seal and completely
prevent bacterial invasion. Based on contemporary experience, perhaps such a seal
is not mandatory, or may even be a hindrance, to achieving excellent clinical results.

Implants and Devices

There are three design paradigms for currently relevant osseointegration
implants: a threaded screw, a spring-loaded platform inducing constant compression,
and a press-fit intramedullary stem. We describe the key design and surgical
features of each below and provide a summary in Table 1.
Table 1. Comparison of Osseointegration Implant Systems
OPRA

ILP

OPL

Compress

Material

Titanium

Cobalt chrome
molybdenum

Titanium

Titanium

Retention

Threaded

Press fit

Press fit

Cross pin

Anatomic
suitability

Long bones,
digits

Long bones

Long bones,
pelvis

Humerus, femur

Bone-Implant
Interface

Laser etch

Czech hedgehog
1.5 mm

Plasma spray up
to 0.5 mm

Porous coat, axial
compression

Skin-Implant
Interface

Polished

Polished

Polished

Polished
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Surgical Stages

2

1

1

1

Months from
Implantation to
Full Weight
Bearing

3-18

2-3

2-3

unspecified

OPRA = Osseointegrated Prostheses for the Rehabilitation of Amputees
ILP = Integral Leg Prosthesis
OPL = Osseointegrated Prosthetic Limb

Threaded Screw Implant

Dr. Rickard Brånemark has used this design (Figure 11) since operating on
his first patient in 1990. It is based upon his father’s DOI design and was under
specific investigation since at least 198313. The marketed name is the
Osseointegrated Prostheses for the Rehabilitation of Amputees (OPRA) (Integrum
AB, Mölndal, Sweden). In 2011 laser etching surface finishing was added to improve
osseointegration44. Two surgical episodes are recommended. The first is to screw
the implant into the amputated bone at least 20 mm deep to the distal end, which
buffers against progressive bone resorption. Six or more months later the
transcutaneous abutment is attached, muscle is sutured to periosteum, and skin to
muscle to create a stable stoma21. A prosthetic limb is then attached to the
abutment. The United States Food and Drug Administration (FDA) has approved
OPRA for Humanitarian Device Exemption for transfemoral use, and trials are
currently underway for transhumeral use45.
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Figure 11. Osseointegrated Prostheses for the Rehabilitation of Amputees (OPRA).
A) Illustration depicting implant placed into the intramedullary canal, retained by a threaded screw
design. B) Focused view of current style implant with scanning electron microscope zoomed window
of the surface texture provided by laser etching. C) Radiograph of OPRA implanted in a femur.

Spring Loaded Constant Compression Implant
The Compress (Figure 12) (Zimmer Biomet, Warsaw, Indiana, USA) was
developed during the 1990s46 and it has been used surgically since 200047 as an
arthroplasty megaprosthesis in situations such as bone tumor resection. It was later
modified to accommodate a transcutaneous implant, with patient trials beginning in
201246. The Compress is made of titanium, featuring a porous distal bone end
platform. A thin intramedullary pin is coupled to this platform and anchored to
proximal bone by smooth cross-pins. Turning a nut in the pin mechanism leads to
progressive force applied to the bone by the platform via a Belleville disk washer
spring mechanism. The theory is that an immediate and constant force applied to the
bone end should promote bone integration, regardless of the patient’s actual weight
bearing46,48. A smooth transcutaneous adapter interfaces with the prosthetic limb.
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The Compress is not commercially available; its FDA trial is currently in planning
stages45.

Figure 12. Compress.
The distinguishing feature of this device compared to the others is that the cross-pin design allows a
screw and nut apparatus to transmit force from a Belleville spring-style washer system directly to the
end of the residual bone, resulting in a compressive force, for which the product is named. The
abutment is polished at the skin interface, and connection to a prosthetic limb is achieved with a
customized attachment. Immediate implant retention is achieved via the unique spring and cross-pin
mechanism. The main difference between the tumour endoprosthesis currently commercially
available and the transcutaneous osseointegrated implant configuration under trial is the addition of a
transcutaneous taper sleeve (intellectual property not available to be shown in photography). A)
Exploded schematic of the device in approximate proximal-distal level as would be for a femoral
amputee, once assembled. 1, transverse/retention pins. 2, anchor plug. 3, spindle with hydroxyapatite
coating at bone interface. 4, Compress nut. 5, temporary compression cap before nut placement. 6,
centering sleeve to position anchor plug in centre of intramedullary canal. B) Illustrated cross-section
schematic of the device showing approximate in situ component positions. 1, transverse retention
pins. 2, bone. 3, anchor plug. 4, centering sleeve. 5, spindle. 6, Belleville washers. 7, taper. 8,
Compress nut. C) Radiograph of Compress in a femoral amputee. Arrow 1 identifies the
transcutaneous taper sleeve. Frame A is provided for use by Zimmer Biomet. Frame B is adapted and
published with permission from Springer Nature. International Orthopaedics. Compressive
osseointegration promotes viable bone at the endoprosthetic interface: retrieval study of Compress®
implants. Kramer MJ, Tanner BJ, Horvai AE, et al. 2007. Figure 5C is adapted and published with
permission from Springer Nature. Der Unfallchirurg. The Compress® transcutaneous implant for
rehabilitation following limb amputation. McGough RL, Goodman MA, Randall RL, et al. 2017.

Press-Fit Intramedullary Stem
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Implants of this category are shaped like a rod, curved to match an average
femur radius of curvature, with a wide distal platform against which the transected
bone end will abut. Each design has various distinguishing features.
The oldest implant from this category (Figure 13) was designed by Dr. Hans
Grundei, first used in 1999, and was named the Endo-Exo (ESKA Orthopaedic
Handels GmbH). Unlike all other contemporary implants, the material is a cobalt
chrome molybdenum alloy. Key design features are a stabilizing lateral bracket with
a rough surface and a 1.5 mm deep Czech hedgehog surface (three dimensional “+”
sign) into which bone grows. However, the lateral bracket seemed to interfere with
proper placement and stoma healing issues were attributed to the rough implant
surface at the skin interface. Thus, the bracket was removed in the first revision, and
later the skin interface was polished. The current version of the implant is called the
Integral Limb Prosthesis (ILP) (Orthodynamics GmbH, Lübeck, Germany). All
versions connect to the prosthetic limb via a dual cone transcutaneous adapter. The
ILP is used in Germany, the Netherlands, Iraq, and Australia, but does not have FDA
approval45,49.
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Figure 13. Press-Fit Intramedullary Stem Endo-Exo and ILP.
Endo-Exo (A and B) and Integral Limb Prosthesis (ILP) (C). All iterations of this implant are made of
cobalt chrome molybdenum, with an intramedullary nail-type stem featuring onlaid 1.5 mm Czech
hedgehogs (a three dimensional “+” sign, featured in Figure frame A) to promote bone ingrowth. All
models achieve immediate implant retention via the press fit implantation, analogous to hip
arthroplasty, and the external prosthetic limb is mounted via a multi-component dual cone and screw
system. A) The original version of this device featured a distal collar which was porous coated to
promote skin adhesion, and a lateral stabilizing bracket to fit over the external bone surface to
enhance torsional stability. Early failures were attributed to this bracket and the rough collar, which
prompted modifications. B) A revised version retained the bracket but polished the collar. C) The next
version, renamed to ILP, removed the bracket and coated the collar with titanium niobium oxynitride
ceramic to prevent skin adherence. Note that bone osseointegration is only designed to occur at the
textured surface approximately 1.5 cm proximal to the abutment, not on the smooth surface between
the abutment and the textured surface. 1, proximal cap screw. 2, ILP body with main portion textured,
distal flare untextured, abutment highly polished with titanium niobium oxynitride ceramic surface. 3,
dual cone abutment adapter. 4, safety screw. 5, taper sleeve. 6, distal bushing. 7, permanent locking
propeller screw. 8, temporary cover screw. Frame A is adapted and reprinted by permission from
Springer Nature. Sports Engineering. Direct skeletal attachment prosthesis for the amputee athlete:
the unknown potential. Muderis MA, Aschoff HH, Bosley B, Raz Guy, Gerdesmeyer L, Burkett BJ.
2016. The zoom-in box of ILP texture is adapted and reprinted by permission from Springer Nature.
Der Orthopäde. Juhnke DL, Aschoff HH. Endo-Exo-Prothesen nach Gliedmaßenamputation. Der
Orthopäde . 2015. Frame B is adapted from the article Kennon RE. A Transcutaneous Intramedullary
Attachment For AKA Prostheses. Reconstructive Review 3(1), licensed under Creative Commons BY
4.0. Frame C is adapted and reprinted by permission from Springer Nature. Operative Orthopädie und
Traumatologie. Implantation der Endo-Exo-Femurprothese zur Verbesserung der Mobilität
amputierter Patienten. Aschoff HH, Clausen A, Tsoumpris K, et al. 2011.

While training with the surgeon who designed the Endo-Exo, I proposed the
use of a highly polished titanium niobium surface, which in fact did significantly
improve stoma healing. After using the ILP in my own practice for several years, I
designed the Osseointegrated Prosthetic Limb (OPL) (Permedica Manufacturing,
Milan, Italy) in 2013 (Figure 14). Maintaining the press-fit stem concept, key
modifications to the ILP were: 1) to use the more osteoconductive titanium Ti6Al4V,
2) create surface pores of 500 μm, 3) design a fluted proximal half to prevent rotation
during insertion and early loading, 4) include a tapered proximal abutment which can
mate with an arthroplasty implant, 5) texturing the surface with a coarse plasma
spray of 500um on the distal half and 150 μm on the proximal half. This different
texture design promotes preferential osseointegration distally, whereas the proximal
part serves more to prevent stress shielding. The distal half of the implant is 1 mm
wider than the proximal half, and the proximal half has 10 flutes each 1 mm tall to
maintain initial rotational stability. While all these modifications are believed to be
important, the decision to coat the distal portion of the stem, including the abutment
surface, seems critical, as it prevents the issue of distal bone resorption seen in
patients with ILPs (the most distal portion of the ILP stem is untextured). The OPL is
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widely available around the world including Australia, the Americas, Europe, the
United Kingdom, and the Middle East45,49,50.

Figure 14. Press-Fit Intramedullary Stem Osseointegrated Prosthetic Limb (OPL).
Three models exist, labelled A, B, and C. The OPL is a forged titanium alloy stem-shaped implant
whose surfaces have a plasma-sprayed coating, up to 0.5 mm thick, to promote bone ingrowth and
rapid integration. The external portion of the collars are treated with titanium niobium oxynitride
ceramic to promote smooth soft tissue gliding, limiting the probability of symptomatic soft-tissue
adhesion and tethering. Proximal fluted fins provide initial rotational stability, akin to a Wagner-style
hip arthroplasty stem. (Figure frame A) OPL types A, B, and C as labelled at top, with matching dual
cone abutment adapters. Type A has a flat abutment with a relatively long smooth collar, and a
proximal tail which is tapered to accept an extension nail or an arthroplasty attachment, when
indicated. Type B has a conical abutment which embeds into the distal bone with a smaller smooth
extra-osseous collar; these also possess the tapered tail adapter, identical to Type A. Type C features
the same abutment and collar style as Type B but the body is shorter, and instead of a tapered tail
adapter there is a 135 degree hole bored near the proximal tail to accept a femoral neck screw which
can prophylactically be used to prevent neck of femur fractures. This type is most suitable for short
femoral residua. All models use a similar dual cone connection mechanism to the external prosthetic
limb. All models’ dual cone adapter features titanium niobium oxynitride ceramic at the portion
exposed to skin to prevent skin adhesion. (Figure frame B) Exploded view of a Type A implant in
approximate proximal-distal level as would be for a femoral amputee, once assembled. 1, proximal
cap screw. 2, OPL body. 3, safety screw. 4, dual cone abutment adapter. 5, permanent locking
propeller screw. 6, proximal connector. 7, prosthetic connector. (Figure frame C) Radiograph of OPL
Type A in femoral amputee.

Two other implants in this category include the Percutaneous
Osseointegrated Prosthesis (POP) (DJO Global, Austin, Texas, USA) and the
Intraosseous Transcutaneous Amputation Prosthesis (ITAP) (Stryker Orthopaedics,
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Kalamazoo, Michigan, USA). Limited information is available regarding either. The
POP features only a few cm of textured surface at the distal portion51 and was first
implanted in 201552, with only preliminary outcomes of 10 patients being reported53.
POP is not approved for routine use anywhere though further investigation is being
considered45. The ITAP featured hydroxyapatite coating to the intramedullary
component as well as the transcutaneous portion. The hydroxyapatite lining did not
provide adequate intramedullary retention and led to skin problems. The ITAP
concluded its trial and will not be marketed54.

Theoretical and Practical Appraisal of Designs
An ideal osseointegration implant should provide rapid full weight bearing,
resist infection, be mechanically durable, be scalable to various size bones such as
extremely short residual limbs or those with capacious canals, be technically familiar
to a broad audience of surgeons, permit simple management of expected
complications such as patient injury, accommodate adjacent joint arthroplasty, be
reasonably removable in cases of implant failure or untreatable infection,
accommodate future prosthetic and neural connective technology, and minimize
manufacturing and utilization cost. The remainder of this section briefly reflects on
the actual or theoretical issues relevant to the various implant designs. Because of
the different maturity and eras of use among the implants, a valid comparison of
outcomes is difficult to perform.

Although the OPRA was the first to demonstrate that osseointegration is a
viable technique, several design features seem suboptimal. Paramount is the screw
concept. Manual creation of a straight tunnel (for the screw track) in a non-straight
tube (bone) can lead to an in-out-in trajectory, due to misjudging the curvature of the
bone or inaccurate determination of diameter given the non-circular canal shape of
some bones (these issues are identified in the OPRA technique guide55). Second,
because the implant is screwed into position without a load applied until the second
stage is completed, bone ingrowth may be delayed or reduced (Wolff’s Law)56. For
this reason, the designer recommends implants should be placed 20 mm deep.
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Further, the screw design may lead to body weight force only being transferred
through a limited number of threads, leading to potential implant twisting if a patient
applies a strong rotational moment through the prosthesis. It is acknowledged that
no documented event of this third concern has been identified. The OPRA is the only
system which has documented use for small digital prostheses57, non-limb
prosthesis58 and neural control adaptation (e-OPRA)59.

The immediate and constant end compression provided by the Compress
seems beneficial: it should prevent situations of distal stress shielding, minimize
bone resorption and optimize bone density due to constant force application.
However, placing the cross-pins in the proximal bone for eventual anchoring
sometimes leads to pin misdirection or breakage, increasingly likely as soft tissue
around the bone increases. Additionally, despite a centering guide, achieving the
correct orientation remains difficult and can lead to improper loading at the distal
bone. Fractures in the residual limb due to patient injury tend to result in the implant
also being damaged and requiring revision and at least a small additional bone
resection46. While this complication is likely infrequent, nonetheless it is inevitable in
a certain percentage. This may lead to difficulty treating these patients if they are not
near a surgeon with specific implant experience, or for patients whose bone is
initially very short this may result in a uselessly short residual bone. Furthermore, the
Compress is not suitable for bones with cortices less than 2.5 mm thickness. This
likely excludes a large proportion of amputees due to cortical thinning resulting from
disuse osteoporosis. The technical difficulty and limited indications make the scope
of use of the Compress limited to younger, healthier bone in patients with relatively
recent amputation and it has so far been used principally in oncology.

The press-fit intramedullary stem design, particularly the OPL, achieves many
of the previously stated implant goals. Since it requires no centering or retention
devices, the tools needed for implantation are a scalpel, an appropriately sized
implant, flexible reamers, broaches, a mallet and suture. Similarly, although a
customised removal set can speed extraction, it can be removed with simply an
osteotomy of the surrounding cortical bone subsequently reduced, fixed and
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retained. The monoblock construction is familiar to orthopedic surgeons and can be
easily sterilized in any autoclave. Its texturing has proven to facilitate stable
osseointegration within a few weeks; patients who sustain periprosthetic fractures
have all been able to retain the implant, have routine fracture care with standard
plates and screws and regain independent ambulation at or above their preimplantation level60. The full body texturing has allowed the proximal portion to be cut
short and successful osseointegration has been achieved to just the distal portion
and abutment. The OPL is the only implant to have been used in patients with an
associated total hip61 or knee62 replacement.

With the origins and foundation of PEPOL summarised, I will focus on how I
became involved and eventually the preeminent surgeon, in osseointegration for
amputees.
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MY BODY OF WORK: IMPROVING AMPUTEE LIFE VIA OSSEOINTEGRATION

Lower extremity amputation (LEA) is associated with substantial quality of life
(QOL) reduction. Pain and ability to wear a prosthetic limb are factors directly
associated with the amputee’s extremity which predictably lower QOL63. Indirectly
associated factors include employment, social support and depression64. While
difficult to tabulate the worldwide LEA census, it has been estimated an amputation
performed every thirty seconds worldwide due to diabetic complications alone65, not
accounting for other causes such as trauma. In 2008 the United States had
approximately 1.6 million lower extremity amputees, a number predicted to double by
205066. A 2014 Australian study estimated LEA incidence as 13% transtibial, 10%
transfemoral and 75% transmetatarsal67. Most patients with lower extremity
amputations above the ankle will seek a prosthesis to aid their mobility.

The typical rehabilitation solution for lower extremity amputees is skinsuspended socket (SSS) prosthesis, with design principles established at least as
early as the 1500s3. Some examples of SSS include: a silicone liner with a distal pin
which clips into the prosthetic leg, layered residual limb socks which suspend a rigid
socket by friction, or a rigid socket that is suspended upon the residual limb the
creation of a vacuum. Unfortunately, significant problems persist. One-third to threequarters of patients develop skin-socket interface problems such as ulcers,
dermatitis, or intolerable perspiration68,69. Mobility and fit is troublesome due to
residuum size fluctuation70 or the feeling of instability from altered proprioception71,72.
Most patients require frequent socket refitting8. Transfemoral amputees often lack
confidence navigating uneven surfaces: one-quarter report a poor or extremely poor
lifestyle73 and 2.2% sustain a residual limb fracture within five years74.

With such substantial population and individual health burden, addressing
patient-prosthesis interface problems would tremendously improve not only each
individual amputee’s health situation but accordingly also that of their family and
friends. Furthermore, when more people are better able to participate in society, the
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communities of these amputees likely can benefit as well. Percutaneous
EndoProsthetic Osseointegration for Limbs (PEPOL) has proven a very effective way
to address the patient-prosthesis interface. This Body of Work summary describes
my academic journey and contributions to the field of PEPOL surgery which have led
to me being the most experienced PEPOL surgeon in the world.

PART 1 - My Clinical and Basic Science Contributions

One of my early publications in 200775 investigated the effect of pamidronate
therapy on children, specifically the radiographic appearance and their subsequent
growth. Bisphosphonates are a class of pharmaceuticals which impair osteoclast cell
reproduction. By reducing osteoclast number, there is less bone resorption, and the
relative predominance of osteoblasts results in a net increase of bone production
and thus bone density. In 1968, etidronate became first bisphosphonate used for
medical treatment, and in the 1980s it began to be used for medical treatment of
postmenopausal osteoporosis76. In the late 1990s pamidronate given in cyclical
doses was cautiously being considered for children with fragile bone conditions such
as osteogenesis imperfecta77. An interesting observation was that when
administered to skeletally immature patients in these cyclic doses, a radiographically
dense line was observed which correlated with the timing of administration. Not only
was this visually striking but it would allow skeletal growth to be measured in serial
radiographs. This finding can be of significant benefit to measure the rate of growth
in these individuals, particularly considering children receiving cyclical
bisphosphonate usually suffer from growth disturbances.

It was during my orthopaedic training when I had the opportunity to investigate
these phenomena. Evaluating the serial radiographs and clinical visits of 36 children
with bone fragility, this project had two goals. First, to assess to what extent
bisphosphonate therapy (specifically cyclical pamidronate) might negatively alter
development of the immature skeleton. Secondly, to name this radiographic
phenomenon. The answer to the first question was clearly that no adverse patient
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growth velocity was identified. By clinical measurement as well as assessment with
radiographs, computed tomography, and magnetic resonance imaging, no adverse
bone effects were identified. We ended up coining the term “zebra stripes” to
describe the parallel white-and-black layers seen on radiographs (Figure 15).
Beyond the direct scientific knowledge, I learned about bone metabolism and how it
can be safely and directly modulated with pharmaceuticals, and I learned the
importance of naming. The term “zebra stripes” has the following benefits: it is short
and simple; the evoked image is immediately intuitive upon seeing the radiograph; it
is distinct from any other orthopaedic phrase; and it is a term that children and also
their parents can hear and think about it in relation to themselves or their children,
and not have a negative connotation. The term is now frequently used in routine
discussion regarding cyclic pamidronate therapy for children and is widespread
enough to be easily searchable on PubMed.

Figure 15. Zebra Lines.
Radiograph of the proximal parts of the tibia and fibula, showing multiple zebra lines (small arrows)
and a Harris growth arrest line (large arrow). Reproduced with permission from Al Muderis, M. MD1;
Azzopardi, T. FRCS(Ed)1; Cundy, P. FRACS1 Zebra Lines of Pamidronate Therapy in Children, The
Journal of Bone & Joint Surgery: July 2007 - Volume 89 - Issue 7 - p 1511-1516 doi:
10.2106/JBJS.F.00726.
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Several years later, while in fellowship in Germany, I had another opportunity
to learn about bone metabolism and its manipulation. Total hip arthroplasty (THA),
recently celebrated as the “operation of the 20th century,”78, only became predictably
successful in the 1950s and 1960s following the innovations of Sir John Charnley79.
One of Charnley’s critical innovations was to link the prosthetic femoral head and
stem to the native femur using polymethylmethacrylate (“bone cement”). Bone
cement acts as a grout-type interface agent which provides implant retention by
penetrating the cancellous bone. As bone cement is metabolically inert, there is no
progressive biologic interaction between itself and the bone, and in fact a fibrous
layer tends to form between them over time80. This does not promote bone health
and can ultimately lead to implant loosening.

A cementless implant is the main alternative to a cemented implant. The first
cementless THA implants were used in the 1950s, but routinely successful use was
not achieved until the 1980s81. Those cementless implants relied on a phenomenon
called osseointegration. Osseointegration is defined as the intimate
ongrowth/ingrowth of bone (osteoblasts) onto a foreign material with no intermediary
layer. The phenomenon was observed by researchers as early as 194082,83, but PerIngvar Brånemark was the first to appreciate and consider its use for surgical
applications14, and eventually coined the term in 1977. It was observed to occur best
for implants made of titanium.

Considering that the long-term success with cementless THA was only
achieved starting in the 1980s, 20-year outcomes were only able to be evaluated in
the 2000s. Curious to better understand the longevity of osseointegrated implants, I
helped investigate patients who received Spongiosa-I fully coated cancellous metal
surface THAs84. At a follow-up time of 242-275 months, the implant survival was
quite excellent in this cohort of patients. The probability of survival of both
components at twenty years, with revision for any reason as the end point, was 97%.
The probability of survival of the acetabular component was 98%, and the probability
of survival of the femoral component alone was 86%. Particularly interesting was that
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the probability of component survival was significantly increased among older
patients (70 years or older at surgical date), which was further explored in a related
follow-up article 85. This meant that “old bone” was not intrinsically compromised
bone, but in fact metabolically suitable for cementless osseointegrated THA. I did not
know it at the time, but this recognition influenced many of my later decisions
regarding patient selection for PEPOL surgery. I participated in the publication of a
similar article on another cohort of patients in Germany showing equivalent results86.

I began my orthopaedic surgery practice in 2009 after completing fellowships
in Germany in arthroplasty and adult limb reconstruction, which included exposure to
PEPOL. I recognised the potential significance of this revolutionary rehabilitation
surgery so I knew I had to include it in my own practice, for Australia’s amputees. As
with any surgery, understanding complications and how they happen, so as to work
to minimise their frequency and severity, is critical to the safety of PEPOL, I
partnered with a group in the Netherlands to prospectively evaluate 86 patients (91
cases) over a four year period87. All patients were followed for the customary
minimum two years (24-71 months), and all adverse events were documented. At
this early stage in my career, 31 patients had an uneventful course. Twenty-nine
experienced soft tissue infection. Twenty-six others experienced problems such as
soft tissue redundancy or stoma hypergranulation requiring intervention. This paper
identified a number of interesting outcomes with several clinically important
conclusions. First, it confirmed that press-fit PEPOL using spongy metal surface
cobalt-chrome implants coated with titanium, were successful at achieving strong
osseointegration. This is very similar in principle to the cementless osseointegration
article I had previously written. Next, none of the patients experienced a catastrophic
adverse event such as death, systemic illness or disability, or proximal level
amputation. Another important lesson was the difficulty of managing the soft tissue.
Skin tends to become loose when its native attachments to underlying fascia and
muscles are disrupted, and also when muscle atrophy occurs following extended
periods of reduced activity as is often the case for amputees. Further, amputee skin
has been compressed and stretched non-physiologically for years when they use a
socket prosthesis. Clearly, soft tissue management had to be an essential
consideration in future PEPOL surgery. A final major impact of this paper was the
33

establishment of a grading system for infection as related to osseointegration (Table
2). I introduced this grading system, which remains the most widely used system to
grade osseointegration infection87. The system differentiates first to what extent the
infection invades the body (skin-only, soft tissue deep to skin, bone infection, or periimplant infection). It additionally identifies how much intervention was required to
manage the infection (oral antibiotics, intravenous antibiotics, surgical intervention,
or implant removal). This provided a language for future surgeons to use when
considering and presenting their infection cases.

Table 2. Classification of Osseointegration Infection
Level of Severity

Symptoms and Signs

Treatment

Grade

Low-grade soft-tissue
infection

Cellulitis with signs of
inflammation (redness,
swelling, warmth,
stinging pain, pain that
increases on loading,
tense)

Oral antibiotics
Parenteral antibiotics
Surgical intervention

1a
1b
1c

High-grade soft-tissue
infection

Pus collection,
purulent discharge,
raised level of Creactive protein

Oral antibiotics
Parenteral antibiotics
Surgical intervention

2a
2b
2c

Bone infection

Radiographic evidence
of osteitis (periosteal
bone reaction),
radiographic evidence
of osteomyelitis
(sequestrum and
involucrum)

Oral antibiotics
Parenteral antibiotics
Surgical intervention

3a
3b
3c

Implant failure

Radiographic evidence
of loosening

Parenteral antibiotics,
explantation

4

At this point, having some early experience with osseointegration patients, I
wanted to confirm whether the improved patient activity would produce objective
improvements in their bone health, measured by cortical bone thickness and density.
Amputee bone is not loaded evenly when they are reasonably mobile, so they tend
to become osteopenic or osteoporotic88. Wolff’s Law suggests that should these
patients become more active after PEPOL, they would walk more and the load from
walking would be transferred directly through their residual bone and proximally
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through their entire skeleton. I began two studies which took several years to
complete, as patients had to be enrolled and then have adequate time to ambulate
and load their bone following surgery. Evaluating 28 patients for periprosthetic bone
remodeling at about 3 years after PEPOL89, we found that the bone immediately
surrounding the prosthesis actually decreases in density but increases cortical
thickness. In a related study of 48 PEPOL patients90, the ipsilateral femoral neck
bone density increased at 1-3 years following osseointegration, much more so for
patients who had a stem-only style implant rather than a stem with a fitted femoral
neck screw. These papers utilised the term “reverse Gruen zone” introduced in one
of our prior radiographic evaluation papers91, which visually identifies regions
surrounding the PEPOL, a term modified from the original term “Gruen zones” used
for THA92. It seems clear that Wolff’s law of bone remodeling occurring in response
to loading remains true for these patients, and thus excessive fixation appears to
induce undesirable stress shielding (the reduction of bone density due to load
transfer of a non-skeletal load bearing implant)93. To further explore the unexpected
thick-not-dense bone appearance identified in the former paper, we have been
working with an advanced radiographic modeling team, from Cambridge University in
the United Kingdom, who can determine cortical bone density and thickness
immediately next to metal implants using specialised artifact reduction software. It is
anticipated that not only will data from these studies help us understand the postoperative bone remodeling, but perhaps also help us better plan preoperative
surgical care and optimisation for amputees.

With many of the most pressing aspects of PEPOL being established in these
papers, and with my insights from performing an increasing number of surgeries on
amputees, I became motivated to expand PEPOL to a wider population. A previous
PEPOL surgeon had recommended only the absolute narrowest criteria of amputees
should be considered for PEPOL: very healthy and relatively young patients94. That
would include the civilian population who have amputations secondary to traumatic
injuries and potentially also military veterans. Indeed, we specifically invested in a
military cohort and identified most do quite well, as they were healthy and active
immediately before having a traumatic injury95. Another project I led revealed young
healthy athletes were also particularly enthusiastic about the benefits
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osseointegration provided to their sporting endeavors96. But when considering all
amputees as a whole, this limitation excludes the majority of potential patients.
Based on the aforementioned research, my clinical and research teams and I felt it
was safe and purposeful to carefully expand our indications. The following series of
case reports and case series helped prove that in fact, when appropriately
performed, press-fit PEPOL is safe and beneficial for more patients than were
traditionally considered.

The first tradition that we felt could be safely improved was that of two surgical
stages. Prior surgeons advocated for, and only performed, two-stage surgeries for
PEPOL94,97. The reason for this was to give the bone-anchored portion of the implant
enough time to establish strong osseointegration so that when it was loaded, there
would not be an early catastrophic failure due to bone-implant loosening. Indeed, a
two-stage protocol is what I employed when first starting98. All 50 patients were
followed for at least one year and all achieved ambulation on their osseointegrated
prosthesis98. The patient-reported outcomes and objective mobility tests improved
significantly for the cohort98. However, based on this experience and that of the
cementless total hip articles described above, along with the basic science provided
by other researchers in the 1970s41, the established science and clinical experience
suggested that light loading and tension should present no risk of loosening
immediately after surgery, and by 7-10 days the maximum pull-out strength is likely
achieved. We therefore developed a protocol for a single-stage surgical treatment
plan99, and nearly all subsequent patients have been cared for with a single surgical
event. We have not noted issues with increased pain, implant retention, infection, or
other problems.

Many amputees also experience degenerative joint disease, leading to
arthritic pain. These patients may seek PEPOL for its mobility and QOL benefits, but
also have hip or knee arthritis which also significantly reduces their mobility and
QOL. Traditionally, these patients would have to choose one or the other: PEPOL or
THA/TKA. Considering that I am a high-volume hip and knee replacement surgeon,
as well as a PEPOL specialist, I felt it would be safe to provide both a joint
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replacement and PEPOL for appropriate patients. In 2015 we published our case
series of four amputees who had a TKA in combination with tibial osseointegration
(Figure 16)62. As the PEPOL was linked directly to the TKA, two surgical episodes
were necessary, despite our preference for a single stage surgery. In the first
episode, a relatively typical TKA surgery was performed. Notably, the tibial
component was designed to be osseointegrated into the bone rather than relying on
cement retention, as is most common for TKAs. The reason for this is that the
subsequent PEPOL was linked directly to this tibial component; if cement retention
were to be used it would be more likely to eventually become loose with
multidirectional forces acting upon the implant-cement-bone interfaces. Whereas
with an osseointegrated retention, the biologically active bone would continue to
remodel and hold fixation in response to the various stresses. Therefore, at 4-6
weeks following the first surgery, the second surgery to connect the PEPOL to the
tibial component was performed. In this series, one patient experienced a superficial
infection that did not require further surgery, and all four patients improved their selfreported subjective satisfaction and objective mobility as measured by the Six Minute
Walk Test. Similarly, three transfemoral amputees had an osseointegrated THA
performed, also with 5-8 weeks separating the two stages61. The thought process for
this was identical to that of the TKA. Just as in the TKA, one patient experienced
superficial infection which did not require further surgery. All patients improved on
their self-reported QOL surveys and also their objective mobility tests.

37

Figure 16. AP and lateral radiographs of a patient who has a total knee arthroplasty connected to a
tibial osseointegration prosthesis.
Reproduced with no permission necessary from Khemka A, Frossard L, Lord SJ, Bosley B, Al Muderis
M. Osseointegrated total knee replacement connected to a lower limb prosthesis: 4 cases. Acta
orthopaedica. 2015 Nov 2;86(6):740-4.

Patients with potentially compromised bone geometry or quality was another
potential contraindication. Standard PEPOL implants are 16 cm long, and while it
was known that less than full implant contact could result in a successful outcome,
some patients had as little as 3 cm of residual femur remaining. This was considered
an extremely high risk for failure to osseointegrate. Not only would an unsuccessful
osseointegration be harmful and costly to the patient which would require additional
surgery, but they may not have enough bone remaining to reattempt
osseointegration. The solution I innovated was to use an intramedullary lengthening
nail to make the bone longer before attempting osseointegration (Figure 17).
Complicating matters even more was the fact that the shortest lengthening nail was
13 cm, and as aforementioned, many of the patients had residual femurs lengths that
were substantially less. So, we had to also innovate new ways to link the lengthening
nail to such a short bone. I came up with two strategies: linking the bone to the nail
using a cable technique, and eventually the preferred option was to link them using a
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locking plate which was bent to fit during surgery100. Even though some patients
required adjuvant surgery to provide bone graft, all eventually received their PEPOL,
and we are in the process of analyzing their outcomes for upcoming submission as
well.

Figure 17. Femoral Lengthening Technique.
(A) Triple cable lasso technique. The nail extended beyond the femur, so the following technique was
used to link the nail to the distal femur segment. Two holes were drilled in the distal segment, each
passing transcortically through both the lateral and medial cortices. One cable was passed through
each pair of drill holes, then through the distal limb lengthening nail (LLN) hole (indicated by arrows).
Both cables were gently tightened and routinely secured. Because bone amputated years before can
be osteopenic, these cables can cut through after initiating distraction. Thus, a circumferential cable
(indicated by arrowhead) secured the 2 longitudinal cables to the distal segment, capturing them
transversely around the strongest portion of the remaining bone, the cortex. (B) Contoured locking
plate technique. A one third tubular locking plate (indicated by arrow) was contoured around the distal
femur which allowed one screw (indicated by arrowhead) to capture the distal limb lengthening nail
(LLN) hole. One long intracortical screw (indicated by asterisk) and 3 additional unicortical screws
linked the nail to the distal bone segment.

Perhaps the most important category of amputees to remove from
contraindication are those whose amputations were from diabetic or vascular
etiologies; many patients have both comorbidities. In the United States of America,
more than half of lower extremity amputations are performed due to complications
resulting from diabetic and/or vascular pathology101 and the rate of amputations for
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diabetic patients is 10 times that of non-diabetic patients102. From 2013 to 2016,
eight patients whose amputation was due to diabetic complications were treated with
PEPOL103. As diabetes mellitus carries an increased risk of infection for many
orthopaedic surgeries, particularly when the glucose levels are uncontrolled104, we
ensured they all had improved their diabetic control since the amputation and had
maintained long term stable glucose and A1c levels. Through one year of follow-up,
all patients had improved objective mobility performance; specifically, five patients
were confined to a wheelchair before PEPOL but were independently ambulatory
afterward. Two patients required surgical debridement for soft tissue infection, but all
retained their implant. A longer-term follow-up study of 56 patients is currently in
preparation for publication, and early analysis suggests similarly favorable outcomes.
Immediately following the recruitment of patients with diabetes, we treated five
patients with amputation due to complications of peripheral vascular disease105.
Three patients were wheelchair-bound before PEPOL, whereas one year later all five
patients were independently ambulatory. Two patients had one episode of superficial
soft tissue infection. Encouraged by this cohort’s successful outcomes, we recruited
more patients who were followed longer. This article was recently accepted and is
currently in press106. Following six patients for 3-6 years after PEPOL, all patients
improved the objective mobility performance, wore their prosthetic legs at least 12
hours daily, and remained independently mobile. Three patients required soft tissue
debridement. One patient developed a myocardial infarction and died. These studies
into the biological feasibility and safety of PEPOL for patients whose amputations
were due to diabetes and/or vascular disease -- the two most common causes for
amputation worldwide -- are truly critical. They prove that a tremendous proportion of
amputees may be able to be treated with PEPOL, something that was previously
considered unreasonable.

Another frontier my team and I pioneered was the simultaneous amputation
and osseointegration of patients with an intact but functionless or QOL-impairing
limb. A common example of such a patient is one with chronic pain. While there may
be multiple reasons for chronic pain, we focused on one specific cause: complex
regional pain syndrome (CRPS). CRPS is characterised by, among other things, the
inability to alleviate the pain due to the inability to specifically identify the cause of
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the pain. CRPS is a diagnosis of exclusion, so they are unable to be treated for
identifiable pain-causing pathology such as vascular insufficiency, infection, arthritis,
or other discernible discrete pathology. There is controversy surrounding amputating
an extremity for anything other than life-threatening concerns. However, if a limb is
so painful as to confine patients to wheelchairs, prevent them from seeking work,
and requiring narcotic and other addictive medications in an attempt to alleviate the
pain, the limb would almost certainly be considered more of a pathologic situation
than a benign, let alone functional, appendage. Prior surgeons have reported that
amputating proximal to the level of symptoms reliably alleviates CRPS pain107. The
trouble is that wearing a socket prosthesis is very tiring for adults and often is not
actually achievable, leading to many patients now having substantially reduced pain,
but effectively non-ambulatory108. Furthermore, there is always the fear of
developing CRPS in the residuum due to problems with the skin-socket interface. I
was presented with three patients who had unrelenting CRPS of the lower leg, who
had unresolvable pain despite years of physical and pharmacological therapy. They
were unable to ambulate, had dropped out of school or lost work due to their pain,
and were on narcotics and other addictive medications. Following transfemoral
amputation and PEPOL, all patients were again able to achieve independent
ambulation, regained employment, or returned to school, and have been able to walk
stairs and uneven surfaces without issue. One patient pursued additional nerve
surgery without consultation and experienced additional pain and is undergoing
corrective nerve surgery to address that pain109. Publishing this series was very
important not only because it identified that patients with this specific diagnosis can
do well after PEPOL, but more because no other publications report performing
simultaneous amputation with osseointegration as single stage surgery for this
devastating condition.

One case report on PEPOL for femoral deficiency110 inspired providing
PEPOL to a patient with a hip disarticulation. A soldier who had sustained an
explosive rocket injury to his leg had been managed with a hip disarticulation in order
to save his life. However, that left him confined to wheelchair mobility as he was
unable to fit a socket prosthesis without severe pain. Never before had PEPOL been
performed for a non-tubular bone (radius/ulna, humerus, tibia, femur). Planning this
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surgery required many geometric considerations that were far beyond what is typical.
Whereas extremities have substantial motion and are already positioned in a way
that people can rest and sit, a device anchored to the pelvis cannot move. The
positioning must be in a way so as to not only allow ambulation but perhaps more
importantly, that permits the patient to sit and lie down to sleep. An additional step
into the unknown with this surgery was whether the pelvis would be sturdy enough to
support a patient’s weight in the geometry that was introduced. Whereas tubular
bones are designed for axial loading, the pelvis does not normally support weight the
same way. As such, we relied on tangential instead of circumferential cortical bone
contact. Fortunately, through careful planning and technical execution, the patient
achieved independent ambulation and has resumed work as a livestock farmer, can
carry two-handed objects, and can even ascend and descend a flight of stairs
without using a railing111.

An additional very large group of amputees that has been nearly neglected by
the entirety of PEPOL surgeons is transtibial amputees. Only six publications report
on 27 total transtibial osseointegration (TTOI) surgeries, each documenting under
ten cases (Figure 18)62,105,112–115. I commenced transtibial PEPOL in 2014. Knowing
this was a future groundbreaking area of research, we formally planned a study of
these patients116. We have submitted a study of 91 patients with 102 transtibial
PEPOL procedures, which represents almost four times the existing number of
patients reported by all other researchers. We hope this report will be accepted later
this calendar year.

42

Figure 18. (A) Clinical photograph and (B) radiograph of patient with a transtibial osseointegration.

Two papers investigated the management of two less common complications,
but which had never received focus before. First, that of implant-patient size
mismatch. As PEPOL remains uncommon worldwide, some surgeons are attempting
to perform the procedure but may not have adequate implant sizes available. A
surgeon who may be treating only one patient with PEPOL may try to minimise costs
by custom-producing only a few implants of varying size, according to the
preoperative templating performed based on patient imaging. In one case, this led to
the largest available implant still being too small for the patient’s true intramedullary
diameter50. That surgeon decided to cement the implant in place to provide a safe
chance for the patient to have PEPOL-like mobility. Although the first few months this
patient reported a good experience, within a year the implant loosened and had to be
removed. That patient went on to have true PEPOL surgery after successful revision
and is now ambulatory.

The other paper that focused on management of complications looked at
periprosthetic fractures60. Along with infection concerns, this is the other most
frequently mentioned concern among surgeons considering PEPOL. Indeed,
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periprosthetic fracture and its management is a major area of concern for total joint
replacement117. Considering that PEPOL patients have an acute change in their limb
attachment (due to the PEPOL now being the prosthesis attachment point) they
could be at increased risk of falls. Or alternatively, if their bone is so osteopenic as to
be unable to bear their weight it might fracture with very low forces. Fortunately, our
study revealed fractures occurred in only 6% of all patients who had PEPOL, and
only in transfemoral patients. All patients could have standard treatment that is
available at almost any hospital that provides orthopedic fracture care (Figure 19). All
the patients who experienced a fracture regained independent mobility. Those were
all important insights from that paper that no other researcher had previously
identified. Additionally, we learned that nearly all fractures occur within 1 year of
attaining a new prosthetic leg, whether it be the first year after surgery or several
years following surgery. In our opinion, it was the change of balance and
proprioception that was the risk factor. This is a very important point that had not
been previously identified and that made a substantial impact in the way prosthetists
and physiotherapists counsel patients.
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Figure 19. Periprosthetic fracture fixation.
Anteroposterior radiographs (A, C, and D) and image intensification (B) of a 64-year-old woman who
had a left transfemoral amputation for chronic infection after total knee arthroplasty. (A) immediate
post osseointegration appearance (15 years and two months after amputation). (B) she sustained an
intertrochanteric fracture eight months later. (C) she was treated with a hybrid dynamic hip screw with
features of a reconstruction plate. (D) there was persistent discomfort, and the hardware was
removed one year later. She has not needed further care in the subsequent six years.
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As our PEPOL volume became increasingly busy and diverse, it became clear
that we needed to ensure we were providing the very best care for our patients. This
is only discernible by first understanding what the other standards are. One way of
evaluating standards is to systematically review the published outcomes of other
surgeons, so we performed this review118. As very few surgeons perform this
surgery, and because amputee characteristics are so diverse, nearly all published
studies lack the rigor to provide confidence in the parameters they investigate.
Nonetheless, the areas of interest provide excellent insight into what matters, at least
to some patients and researchers. Tactile sensation is important to amputees, as it
helps them better interpret and successfully negotiate the ground they walk on; only
two published studies obliquely investigated this topic, and we are therefore planning
research into this area ourselves. The biomechanics and gait parameters of
amputees is extremely complex; there are intimations of better gait with PEPOL vs a
socket prosthesis, and this is very expensive to appropriately investigate as it
requires a gait lab. PEPOL of course carries an initial expense as it is an additional
procedure (whether or not it is performed simultaneously to amputation or later).
However, whether the long-term costs are justified is important. Two studies have
tried to investigate this but are of insufficient quality to understand whether the better
QOL and mobility can be quantified also with respect to economic cost. Patientreported outcomes are important in all areas of medicine, and unfortunately for
amputees there is only one survey instrument119 and it is not designed for patients
with PEPOL. Patient mobility and energy consumption are the most studied aspects
of PEPOL, and these are generally clear: following PEPOL, patients are equal, or
superior compared to how they were with a SSS prosthesis.

As a world leader for PEPOL surgery, I was requested to write a review of
osseointegration, summarising the currently available implants and techniques, as
well as providing thoughts about where the field may go in the near future120. This
review covered the two then-available press fit stem-type implants (Osseointegrated
Prosthetic Limb and Integrated Limb Prosthesis) as well as two tried but failed stemtype implants (Intraosseous Transcutaneous Amputation Prosthesis and
Percutaneous Osseointegrated Prosthesis), the oldest design screw-type
(Osseointegrated Prostheses for the Rehabilitation of Amputees), and a currently
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investigated active compression type (Compress). The review also details the
morphology, surface design, material properties, and surgical principles of each
implant.

These peer-reviewed articles demonstrate the most important developmental
milestones in my philosophical and academic progression from a young orthopaedic
surgeon to one who is recognised as the world leader in osseointegration. In the
coming sections I will describe techniques that I have not yet submitted for
publication, and design innovations which currently remain proprietary.

PART 2 - My Innovative Surgical Techniques for Osseointegration
Prior to my involvement with PEPOL, there were a few other groups
performing PEPOL with different surgical techniques. One of which was the ITAP
System from the UK at Stanmore, which has been under a complete veil of secrecy
and has not progressed to commercialisation to this date of writing54. The Swedish
system, led by Dr Rickard Brånemark utilising the OPRA screw fixation device
mandates a two-stage surgical technique, minimum six months apart, followed by an
extensive 18-month period of rehabilitation21. Alternatively, the German system, led
by Dr Horst Aschoff utilising the ESKA Endo-Exo Press Fit system also adopted a
two-stage surgical technique with six-eight weeks in between stages and patient-led
post-operative rehabilitation45,49. When I started performing PEPOL I preferred to use
a press-fit implant, so I started using the German ESKA system with two-stage
surgery. However, from the early days I felt the necessity for establishing a robust
rehabilitation protocol that is tailored for different categories of patients. A protocol
that was safe and allowed patients with variable degrees of osteoporosis to progress
through a gradual program of incremental loading, earlier mobility, and return back to
independence.

In 2010 I started performing PEPOL as two stage surgery for above knee
amputees. In the first stage I would make an elliptical incision, usually horizontal at
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the distal end of the stump, resect the skin and subcutaneous tissue down to the
muscular layer, and then depending on the integrity of the prior muscle myodesis or
myoplasty I would make a horizontal incision in the muscle layer down to the bursa
covering the distal end of the bone. Next, I would excise the bursa and resect the
distal most 2.5cm of the skeletal residuum in order to get to healthier cortical bone. I
would then identify the sciatic nerve, resect the neuroma and ligate the distal end
using 1-0 Vicryl, and then embed the nerve into the surrounding soft tissue. The
bone canal would then be sequentially broached using Endo-Exo curved broaches.
The Endo-Exo broaches are cylindrical rasps with multiple sharp triangular teeth of
1.0mm in height, randomly oriented on the broach surface to enable scraping of the
intramedullary surface of the bone. Broaching the canal is performed sequentially by
hammering the broach handle in and out using a mallet until facing significant
resistance and the broach becomes rotationally stable inside the canal. The final
stage of bony preparation involves a face reamer to flatten the distal end of the bone.
Bone that is harvested during this process is then cleaned from any fat and blood
clots, and dried using a sponge. The bone graft is coated over the Endo-Exo implant
which is then press-fit and impacted into the femoral canal using a mallet. The final
implant position is confirmed with an image intensifier.

The soft tissue is then addressed by removing the redundant overhanging
muscles, then suturing the deep muscle layer into the periosteum at the base of the
implant collar. The more superficial muscle layers are myodesed around the implant
collar in a purse string suture fashion. This technique allows the muscles to control
the residuum. The subcutaneous fat is thinned without compromising the blood
circulation to the overlying skin, the excess skin is removed, and the wound is closed
over the implant using skin staples. An occlusive dressing is then applied, and the
stump is bandaged using a crepe bandage.

Patients undergo postoperative rehabilitation including range of motion
exercises and strengthening, stretching to prevent the development of flexion
contractures, and lymphatic drainage. The wound is maintained clean, alternate
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staples are removed at two-weeks post-surgery, and the remainder at the threeweek post-operative mark.
The second stage surgery takes place six weeks after. With the help of an
image intensifier, the centre of the distal end of the implant is located using a
guidewire; a coring device is then inserted over the guidewire, coring the skin over
the implant in a rotational manner. A measuring device is then inserted into the
tapered end of the implant to decide the size of the dual cone by measuring the
distance from the implant to the surface of the skin. The dual cone is then attached
to the implant and secured by the internal screw, along with the taper sleeve, the
bushing, and the distal locking screw.

After the second stage the patients would stay in the hospital for the acute
postoperative period, and after a few days they get transferred to a rehabilitation
hospital. The dressing is usually a dry sterile gauze dressing, webril cotton and crepe
bandage around the distal end of the stoma. It is very common that there will be a
significant amount of serous fluid discharge in the early days, some of which has been
accumulated between the two surgical stages. This discharge settles gradually over
time and the patient usually is fitted with a loading device to allow them to load on a
bathroom scale gradually, depending on their protocol, for a period of two to six weeks.
These patients will then be fitted with their temporary trial prosthesis to learn how to
mobilise with two crutches in parallel bars. The trial prosthesis period lasts
until the patient is comfortable walking with crutches, and then the patient is
transferred to their permanent prosthesis. The progression in rehabilitation protocol is
later discussed in Part Four.

It was after I had operated on my sixth patient, I noticed the development of an
infected haematoma in between stage one and stage two. This developed two weeks
after the first stage. It was at this point the patient returned to theatre and after the
wound was debrided and washed, I noticed that the implant had been solidly fixed
inside the femur, so the decision was then made intraoperatively to proceed to the
second stage rather than waiting another 4-6weeks. Fortunately, this patient did
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extremely well, and this bolstered our confidence in a more accelerated rehabilitation
protocol. It was after this incident occurred on a few occasions when I began to
question not only the necessity of two stage surgery but also the safety. Another
downside of two-stage surgery I found was the significant amount of soft tissue
redundancy that was required to close the skin around the 3cm collar of the German
ILP implant. Based on these two factors, in 2014 I made the decision to perform single
stage surgery.

The move towards single stage surgery resulted in a dramatic shift in our soft
tissue management. I began more aggressive soft tissue excision, resulting in minimal
distance between the bone and the skin, which solved the issue of soft tissue
redundancy. This also resulted in less movement around the soft tissue implant
interface, reducing the potential for inflammation and infection and the need to use a
longer dual cone due to the once overhanging tissue. This transition to single stage
surgery raised the necessity to develop a new implant design that would provide
immediate postoperative stability rotationally and axially, allowing the patient to begin
early loading rehabilitation. In the next section I will describe in detail how we
developed the OPL implant and how that encouraged me to be more confident when
performing single stage surgery.

With single stage surgery, the patient undergoes anaesthetics and is positioned
supine on the orthopaedic table. I perform a larger elliptical or fish-mouth incision into
the distal end of the stump. Depending on the size of the tissue redundancy, I remove
skin and subcutaneous tissue fat down to the muscle layer. I make a horizontal incision
in the muscle layer down to the bursa of the bone. The bursa is excised completely
along with the distal end of the bone, to a healthy margin where there is good cortical
bone. The distal end of the bone is physically and radiologically inspected. Using an
oscillating saw, I remove any excess bony exostoses, shorten excess bone length,
remove severely osteoporotic bone and reshape the distal end perpendicular to the
longitudinal canal allowing maximum bony contact with the shoulder of the implant
collar (Figure 20).
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Figure 20. Face Reamer.
After a new amputation level of the bony residuum is established, the distal end is reshaped with a
special reamer to achieve a perfectly flat surface perpendicular to the longitudinal canal for maximum
bony contact with the implant.

The intramedullary canal is then prepared by sequential reaming using flexible
reamers, similar to what is used with the Endo-Exo implant, harvesting the bone that
is necessary for future bone grafting (Figure 21). Broaching then takes place using the
designated OPL broaches (Figure 22). These broaches are the same shape as the
implant. They have sharp cutting fins in the proximal 80 mm of the broach, and they
have cylindrical impaction grasps in the distal 80 mm to impact the bone in that area.
Sequential broaching is performed until the broach faces resistance to further
impaction with a mallet and provides rotational stability. With this new implant design,
we engineered a face reamer which is drilled to shape the distal end of the femur to
match the shoulder of the implant collar. The bone that is harvested is then
reimplanted, once clean, into the bone and impacted using an undersized broach. The
definitive implant is press-fit into the bone under the guidance of an image intensifier.
The soft tissue is addressed and the nerves are identified, including the sciatic (with
its two branches) and the saphenous nerves. Targeted muscle reinnervation is then
performed by implanting the common peroneal, tibial, and saphenous nerves into
motor branches supplying the biceps femoris, one of the pes, such as semitendinosus,
and adductor longus muscles (Figure 23).
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Figure 21. Preparing the intramedullary canal with Flexible Reamers.
Sequential reaming is performed with a flexible reamer until cortical bone is reached. Bone grafts are
collected at this phase and reinserted along with the final implant.

Figure 22. Broaching
Sequential broaching of the canal with designated OPL broaches prepares the canal into a suitable
shape for receiving the implant. The broaching activities also provide the surgeon direct indication of
the fixation level to help determine the ideal implant size (diameter).
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Figure 23. Targeted muscle reinnervation.
This is often performed along with the primary surgery by implanting the common peroneal and tibial
into motor branches supplying the biceps femoris, one of the pes such as semitendinosus muscles.

The next step is to address the muscle groups. The deepest layers of muscles
are sutured into the periosteum. I always leave the periosteum longer than the bone
in order to allow later suturing with the muscles. I suture the deep layer to the bone
from all angles around the collar of the implant, and then the fascia of the more
superficial muscle layers are sutured around the collar of the implant on both sides, at
3 o’clock and 9 o’clock. I re-anchor the flexors to the extensors utilising their fascia
and around the collar of the bone to provide a proper myodesis around the distal end
of the implant. The subcutaneous tissue fat is then thinned, without compromising the
circulation to the overlying skin. The subcutaneous tissue is closed from both sides of
the wound in a firm fashion to prevent any redundancy, by excising the redundant
tissue. Depending on the shape of the distal end of the residuum, there are two
methods of closing the skin. One is by forming a skin flap over the implant collar and
closing the wound completely, then coring the skin using a special device over the tip
of the implant. This allows the implant collar to protrude through, away from the wound.
If there is insufficient skin to form a flap, then the skin is closed around the base of the
collar allowing the implant to protrude through the wound.
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To this date there is no consensus as to which is the better approach. I trialed
both techniques, and there is no significant difference in the results. Although making
a separate core hole in the skin as a skin flap would provide a more cosmetic healing
wound, it increases the risk of development of skin necrosis of the area on the edge
of the flap, so there are pros and cons with both approaches. Regardless of the
approach, the principle of firm closure to minimise soft tissue movement is essential.
The skin is sutured using absorbable sutures and no drain is left in situ. The dual cone
is then attached to the implant with the internal screw, along with the taper sleeve, the
bushing, and the distal locking screw. These patients commence rehabilitation straight
away from day one after the surgery and the same dressing is used as if it were the
second stage procedure with dry gauze, webril cotton and crepe bandage.

Once I reached the stage of perfecting the surgical technique of transfemoral
PEPOL, I decided to embark on helping a more challenging group of patients, the
transtibial cohort of amputees, as this represents a larger cohort. The majority of the
published literature targeted transfemoral amputees when it came to PEPOL surgery.
Very few attempts had been made to perform transtibial PEPOL by the OPRA and the
German teams. Both groups came to the same conclusion and abandoned doing the
surgery on below knee amputees due to high complication rates. Considering that
below knee amputees share the same challenges that above knee amputees face with
SSS prosthesis, I felt it was only fair to further explore performing PEPOL in this cohort.

I began performing transtibial osseointegration in 2014. As expected, the
journey was not as smooth as with transfemoral amputees and this was due to a
number of reasons. Apart from the lack of data to build our techniques and protocols
on, there were challenges with different anatomy considering the cross section of the
tibia is triangular in shape, while proximally at the metaphysis it widens and becomes
cancellous. These anatomical features mandated a change in design of the implant to
provide initial stability and later osseointegration. The skin and subcutaneous tissue
below the knee is closely adherent to the bone anteriorly and medially while there is
significant bulk of soft tissue (both muscle and subcutaneous fat) in the calf. This
anatomical change in soft tissue bulk necessitated a shift in surgical management
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when compared to my approach with transfemoral amputees, especially given the
presence of the fibula. Furthermore, it has been established that vascularity to the
lower limb decreases distally which results in problems with healing and an increased
chance of surgical failure.

With the aim to maximise osseointegration, I needed to make the implant wider
with a rougher surface to match the cancellous bone of the proximal tibia. This was
achieved by utilising 3D printing. To supplement the initial rotational stability, I added
multiple cross screw fixation through the implant into the tibia (Figure 24).

Figure 24. Radiograph of a transtibial implant showing the rough surface structure of the implant and
three proximal cross fixation screws.

The surgery is performed by making a horizontal incision over the distal end
of the tibia. Care must be taken to preserve the periosteum, as the tibia anteriorly
and medially lies just under the skin. The only separating tissue between the skin
and the bone is a thin bursa, while posteriorly in the calf there is an abundance of
muscle tissue. This soft tissue arrangement makes wound closure around the
implant more challenging. I learnt to make a larger posterior flap in order to provide
sufficient coverage for later closure.
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The bone is then identified and the centre of the canal is located radiologically
with the help of an image intensifier. The aim is to position the implant centrally in the
tibia on AP and lateral views, considering that due to the pyramidal shape of the
proximal tibia, it is possible to malposition the implant in varus or valgus position.
Care must be taken during the reaming and broaching steps to ensure accurate
positioning of the instruments by using frequent x-rays. Furthermore, there is a
significant discrepancy in the cortical thickness of the proximal tibia, as the bone is
very thick anteriorly relative to posteriorly and laterally. This makes reaming and
broaching more challenging as the bone can be excessively thinned posterolaterally
whilst remaining thick anteriorly. Often rasping the anterior cortex is required to
balance the cortical thickness. Once the intramedullary canal is prepared, the
implant is press-fit in a similar fashion to transfemoral PEPOL surgery. Although I
initially incorporated cross screw fixation, I later abandoned this concept as though it
added initial stability, I found it was a contributing factor to failure of the
osseointegration and subsequent loosening. The bulk of the calf muscle is removed,
and the distal end of the fibula is resected 5cm to ensure it is shorter than the
residual tibia, facilitating proper wound closure. Targeted muscle reinnervation is
performed locally at the stump by re-anastomosing the nerves to motor branches of
local muscles. The tibial nerve is re-anastomosed to the soleus muscle, the
superficial peroneal to peroneus longus, the deep peroneal nerve to peroneus
brevis, and the saphenous nerve to the medial gastrocnemius or tibialis anterior
muscles. On occasions the sural nerve is re-anastomosed to the lateral
gastrocnemius nerve motor branch. The muscles are re-attached posteriorly and
laterally around the tibia by suturing them to the periosteum. In a similar manner to a
transfemoral procedure, the wound is then closed using a posterior flap over the
distal end of the implant. The remaining steps are similar to that of a transfemoral
PEPOL surgery.
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PART 3 - My Osseointegration Implant Design Innovations

The Endo-Exo Implant and Subsequent Design Improvements
Due to my clinical experience with patients presenting with complex limb
deformity and amputation, I have been actively researching PEPOL as an effective
treatment option for my patients. I was immediately intrigued by the life-changing
nature that this technology may be able to bring to amputees, especially those who
are unable to tolerate a traditional SSS. Shortly after I started my practice in Sydney
Australia in 2009, I began researching relevant options available in the Australian
market, which opened my journey towards a specialty in this field. While the concept
of PEPOL has been explored by various research teams for quite some time, there
were only two implant designs that reached commercial viability in the market by
2009. These were the OPRA implant originating from Sweden, based on the dental
implant concept, as well as the more radical, orthopaedic open mesh surface
structure design developed by Dr. Ing. Hans Grundei in Germany. Each of the
implant designs carry a number of pros and cons, which through my clinical
experiences enabled me to come up with several design changes to perfect and
revolutionise this treatment technology.

The German implant, now more commonly known as the ILP-System, was
initially registered and manufactured by the German company ESKA Implants as
“Integrales Prothesen System, Endo-Exo Prothese” (translated: Integral Prosthesis
System, Endo-Exo Prosthesis). As part of a commercial asset deal, the UK based
Summit Medical Group acquired the assets of ESKA Implants in April 2010 and
renamed the company Orthodynamics. As a result of that, the Endo-Exo Prosthesis
was renamed to Integral Leg Prosthesis, also known and described as ILP, without
making any design changes. The majority of the ILP components were manufactured
out of cast cobalt alloy (CoCrMo) in accordance with ISO 5832-4, and considers the
natural bow and antecurvation of the femur (r=1,700). In order to ensure a reliable
osseointegration in the femur, the femoral stem has a Spongiosa Metal® surface
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structure, which was also used in various other orthopaedic implants on the market.
Bony integration of the femoral stem is promoted by means of this three dimensional,
macroporous grid structure. The surface features a three-dimensional interconnected
grid micro-architecture which is adapted to the human cancellous bone structure
(Figure 25). This Spongiosa Metal® surface structure is not a coating, but rather part
of the casting process of the implant which makes it unique in nature. This feature
provides the macroscopic potential of not just bony ongrowth but bony ingrowth and
penetration, which lead to complete osseointegration between the implant and the
bone (Figure 26).

Figure 25 Spongiosa Metal®
This was developed to mimic the structure of cancellous bone and is clinically shown to achieve good
levels of bone integration over time 113.
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Figure 26. Figure 26. Magnified image of the Spongiosa Metal® surface showing that this structure is
part of the implant core rather than being a coating. Osseointegration showing the bony penetration.

In the early days, a major obstacle for the success of transcutaneous implants
was considered to be the implant–skin interface due to common complications at this
site including infection, marsupialisation (epithelial down growth and pocket
formation), and permigration (the gradual extrusion of a percutaneous implant
secondary to inappropriate epithelial growth) all of which can ultimately lead to
implant failure. Several attempts have been made by different groups such as the
original ESKA team, the ITAP team in the UK, as well as Dr. Ronald Hugate in the
US, to create a region of soft-tissue ingrowth into the implant in order to form a
concealed implant-skin interface. Materials such as a plasma spray porous skirt
section (Figure 27) or porous tantalum and HA coated flanges (Figure 28) have been
explored in various publications and animal studies. However, clinical evidence
supporting this design has so far been absent. In fact, based on our experience, the
highly porous yet rigid nature of these implant-skin interfaces often resulted in more
irritation to the soft tissue region during ambulation, and made any treatment
strategies for managing infections much more difficult.

59

Figure 27. An older design of the Endo-Exo Implant
Featuring a rough and porous soft-tissue interface (Lunow et al. 2010). An implant designed and
patented in the US also employing a similar approach with a coarse Porous Material Skirt made of
porous Tantulum122.

Figure 28. HA coated implant surface (ITAP).

In contrast with a rough, porous surface structure, I observed that dental
implants, as well as the PEPOL device designed by the Swedish team, made very
little interventions in the stoma region and kept the transcutaneous portion a natural
cylindrical structure. This led to my hypothesis that a simplified stoma management
approach would be more appropriate in this application and was later clinically
demonstrated to be correct. These ideas translated towards the initial
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conceptualisation of a smooth transcutaneous region on the ILP system, which was
the complete opposite to what had been attempted previously. Instead of a rough
region to encourage soft tissue attachment, I adopted a highly polished surface to
decrease soft tissue attachment. A further coating was introduced based on Titanium
Niobium (TiNb or TiNb(ON)) for even lower friction, improved biocompatibility, as
well as antimicrobial properties (Figure 29). The low friction of this cylindrical
transcutaneous region was later shown to offer much better clinical outcomes due to
the following advantages:
● Low friction enables the soft tissue to move up and down naturally during
ambulation, resulting in less irritation, inflammation and infections.
● The inner soft-tissue skin-bone interface naturally reduces and attaches to the
distal portion of the bony periosteum.
● Any potential inflammation or infections can simply be drained through the
interface and easily flushed in a clinical setting whenever required.

Along with improved surgical techniques, particularly in soft-tissue management
as well as adopting a single-staged approach, a complete redesign of the ILP
implant was introduced through the implementation of these concepts, which
resulted in a greatly improved overall success rate of PEPOL at the time.

Figure 29. Newly designed ILP implant.
Reintroduced based on my design inputs featuring a completely smooth distal transcutaneous region
that is highly polished and coated with a TiNbN ceramic layer to achieve minimal friction to the skin.
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Development of the OPL implant
While the improved version of the ILP implant resulted in a much better
clinical outcome, after regular clinical use in my own practice, I further identified
several issues that we were able to improve. First were the underlying material
properties of the cast cobalt alloy (CoCrMo) used in the construct of the ILP design.
This material, while biologically inert, is inherently stiff, often leading to issues such
as stress-shielding and subsequent bone resorption at the distal end of the implant
(Figure 30). The inherent inert nature of CoCrMo also greatly limits the structural
integrity due to the necessity of a non-structural spongiosa region, resulting in a very
narrow core and compromised structural strength (Figure 31). The cylindrical shape
of the implant translates to limited rotational stability of the implant, resulting in
several clinical cases where the implant inadvertently rotated early post-operatively.

Figure 30. Stress shielding at the distal portion of the implant.
While the ILP integrates well with the femoral canal over time through the spongiosa surface, the
distal portion of the implant lacks the coating and as such, results in the reabsorption of the distal
femur end.
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Figure 31. ILP implant cross section.
A mechanical drawing of the cross-section of the ILP implant showing the spongiosa coating region
for bony integration. This spongiosa region provides limited structural support to the overall implant
strength and the load is taken up through the narrow implant core.

In my opinion, the biggest design flaw of the ILP implant was the distal
portion. (Figure 32). The segment distal to the Spongiosa Metal® is smooth and
represents a 15mm area that is 1mm wider in diameter. If this wider diameter is not
accommodated for by the surgeon during bone canal preparation, a fracture can
result during stem insertion. Simply, the original design of the Endo-Exo rasps did
not accommodate for this wider section. Even with successful implantation without
fracture, this section was often the area where stress shielding occurred due to its
smooth surface which did not allow osseointegration. Furthermore, the point of
transition from the Spongiosa Metal® portion of the implant to the smoother wider
area created a stress raiser on the implant. This was due to the fact that the
Spongiosa Metal® portion often is well osseointegrated, while the adjacent smooth
area is not. There have been several cases of implant fracture at the transition
point60.

Figure 32. The ILP implant has a 1mm wider smooth surface segment of 15mm in length.
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In order to overcome these limitations, I began conceptualising the next
generation implant that utilises more modern materials and manufacturing methods.
Based on my experience with many orthopedic devices, titanium alloy became the
obvious choice due to its superior osteoconductivity, lower elastic modulus, and
lighter weight. Taking the successful design characteristics of the ILP implant and
coupling it with a modernized titanium-based manufacturing technology, I was able
to develop a new implant design called the Osseointegration Prosthetic Limb (OPL)
(Figure 33), which has now become the most widely used PEPOL implant in the
world 121.

Figure 33. An overview of the Osseointegration Prosthetic Limb (OPL) implant.
Designed in Australia and manufactured by both Osseointegration International Pty Ltd in Australia
and Permedica S.p.a in Italy.

During the development of the OPL implant, the introduction of the titanium
alloy enabled me to change the implant design from the spongy surface structure of a
cylindrical implant to a plasma sprayed pure titanium coating, identical to many
modern arthroplasty implants. The distal half of the implant is coated with porous Ti
plasma spray that is designed to facilitate rapid osseointegration. In order to provide
immediate rotational stability, the proximal half of the implant was made with ten sharp
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longitudinal fins, 1mm in height, creating grooves inside the inner cortex during
implantation (Figure 34).

Figure 34. A view of the OPL implant showing the distal half with coarse porous coating and a narrow
proximal half with longitudinal sharp fins.

To address the distal bone resorption, I made the distal half of the implant 1mm
wider with a much coarser porous coating. This would allow the osseointegration and
the bone loading to be concentrated distally. The collared part of the implant at the
distal end was also coated with Ti plasma spray coating all along the shoulder region
to provide immediate axial stability (Figure 35). All these features add immediate
stability to the implant design and encourages early osseointegration which facilitated
the transition to single stage surgery.

Figure 35. A view of the OPL implant showing the distal portion with the plasma spray coating along
the shoulders of the collar.
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In addition to the original ILP design, in order to allow the implant to be suitable
for use with a wider range of patient anatomy, I further introduced variants (Type B/C)
to the OPL range incorporating a distal flared portion to reduce implant subsidence as
well as a proximal lag screw option for patients with a short bony residuum (Figure
36). Although the majority of patients are suitable to be fitted with a Type A OPL
implant, the characteristics of Type B & Type C implants were necessary to provide
better coverage of challenging anatomy presentations, especially when working with
traumatic and congenital amputees.

Figure 36. Type A, B C variants of the OPL system.
Designed to enable the system to cater towards patients presented with a standard (Type A), long
(Type B) and short (Type C) bony residuum. The Type B and C implants featured a flared collar distal
end and allowed the implant to recess into the femoral canal. The Type C also features a lag screw
hole to enable additional fixation through the femoral neck when required.

Considering that a significant portion of amputees are elderly and would
eventually develop arthritic changes in the hip joint, I added a proximal taper that can
attach to a modular hip arthroplasty stem (Figure 37).
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Figure 37. The proximal taper of the OPL implant allowing for attachment of a hip arthroplasty stem.

Figure 38. The proximal attachment of a modular hip arthroplasty stem to an OPL implant.

These designs ultimately led to the regulatory approval and commercialisation
of the OPL device in both Europe and Australia, and was recently granted a
worldwide patent 123 application. These new implant characteristics offered by the
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OPL combined with a completely revamped surgical technique and rehabilitation
protocol, which I will discuss in subsequent sections below, enabled the successful
transition to single-staged PEPOL. Compared to the original established precedent
of 8-12 months of rehabilitation, my team and I were able to shorten the entire
reconstruction period to 4-6 weeks, greatly improving the feasibility of this technology
and enabling more amputee patients to be able to benefit from it.

PART 4 - My Innovations in Rehabilitation Strategies for Osseointegration
Patients

In most areas of orthopaedic surgery, the rehabilitation strategies receive far
less attention. Surgeons tend to get more involved with overseeing aspects such as
indications, patient selection, implants, surgical technique, imaging characteristics,
and complication rates. Even for extremely common surgeries such as rotator cuff
repairs, which have long-term engaged therapy after surgery, comparisons of
rehabilitation techniques are almost entirely consensus-based rather than evidencebased124. For PEPOL, only one other author has published a postoperative
rehabilitation strategy, and that remains as a preference without evaluation or
comparison94. I am currently preparing our transfemoral postoperative rehabilitation
protocol for peer review, which is summarised in the table below. Since nearly every
patient is treated with a single-stage PEPOL, I no longer maintain a typical protocol
for patients in between the first and second stage; those who have a two-stage
surgery simply work on their range of motion in their ipsilateral limb before having the
second stage. The Swedish team have their own rehabilitation protocol that is
essentially dependent on slow but gradual loading of the implant, followed by training
while wearing a prosthesis over a lengthy period that may extend to 18 months19.
The Germans did not follow a structured rehabilitation protocol and have not
published anything regarding rehabilitation to date. Considering that I used a very
similar press-fit implant technology to that of the German system, I could not use the
Swedish protocol which was based on a screw-fixation device. I therefore
established an OGAP-OPL rehabilitation protocol in 2010 that would be more
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suitable for press-fit implants. This protocol has been updated over time to
accommodate implant design improvements in accordance with our learning curve
and patient feedback. The rehabilitation process starts the day following surgery and
is divided into six phases (Table 3).
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Table 3. Phases of Rehabilitation
Phase

Prosthetist

PT Goals and
Frequency

Hands-On
Treatment

Exercises

Self-Care

1: Exposure

1. Choose
prosthetic
option
2. Measure
and
template a
training leg

1. Load 50% BW,
good alignment,
minimal pain
2. Control swelling
3. Intact leg SL
balance
4. Full ROM
exercises
5. Fitting with
training leg

1. Gentle residual
limb massage and
lymphatic
drainage
2. Desensitising
therapy
3. Muscle release
of gluteals, rectus
femoris, adductors
as required

1. Static axial
loading 5kg, 20
min twice daily.
2. Increase 5
kg/day until 50
kg or 50% BW

1. Prone lying
2. Showering
3. Incision
remains
uncovered
4. Moderate
sun exposure
can promote
dryness and
bacterial
control
5. Start salt
baths week 2

1. Fitting
and adaptor
education
2.
Adjustment
for
alignment

1. No unsupervised
walking or prosthesis
wear for 2 weeks
(prevent falls)
2. Supervised 2 x FC
walking
3. Balancing with
training leg
4. Independent
don/doff
5. Independence
with HEP with
prosthetic leg

1. 2 x FC for 6
weeks after
prosthesis fit
2. Flat indoor
walking
3. No turns/pivots
4. 5-10 minute
sessions x3 with
rest
5. Stairs: step-to
GAS/SAG
6. Video and
Mirror feedback

1.PT 5-6 days
weekly, 2-3x
sessions daily
for gait training

1. Daily HEP:
strength and
stretching
2. Ice and
compression
pre/post PT
3. Daily salt
baths
4. Weekend
rest
5. Wear
prosthetic limb
for rehab
walking and
exercise only

1.
Alignment
review
2. Weekly
increases in
prosthetic
height
3. Consider
increasing
knee
resistance

1. Independent 2 x
FC walking
2. Improve balance
and strength
3. Ramp training

1. Mostly learning
to “ride the knee”
2. Ramp training

1. Taper gait
training PT to
3-4/week

1. Wear
prosthesis at
meals, rehab
walking, and
exercise only
2. Daily
strength and
stretching

1.
Fortnightly
increase
knee
resistance
2. Achieve
even leg
length
3- Optional:
introduce
microproces

1. Start alternate
crutch gait
2. Increase
prosthesis wear to
near full-day
3. Begin uneven
ground and outdoor
walking

1. Alternate crutch
training
2. Ramp training
3. Hard ground
outdoor walking
4. Controlled
simulated uneven
ground walking
5. Weaving and
tight space
walking

1. Taper gait
training PT to
2-3/week

1. Improve
independence

Fit patients
with strong
bone can be
Fast (0-2
weeks)
Others Slow
(0-6 weeks)

2: Dependence
Patients
introduced to
skills but
require high
supervision

3: Transition
Patients begin
early
independence

4:
Development
Patients
develop their
routines and
preferences
guided by
clinicians
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sor knee

5: Maturation
Patients begin
to determine
and assess
goals

6:
Maintenance
Nearly all
patients
achieve
independence
by 3-6 months

1.
Permanent
full weight
prosthesis

1. Single FC without
gait pattern
regression
2. Improve distance
endurance
3. Progress uneven
ground stability with
single FC
4. Begin stair mode
practice
(microprocessor
knee)

1. Obstacle and
decision
challenges
2. Grass and
uneven outdoor
mobility
3. Fall training

1. Taper gait
training PT to
1-2/week

1. Wear leg
entire day

As required
only

1. Taper to
cane/unaided per
patient skills/goals
2. Independence
with up-stairs mode
(Microprocessor
controlled knees)

1. Progress
obstacle, decision,
surface
challenges

1. Taper gait
training to as
needed only

1. Patient
becomes selfdirected
“expert” in
prosthesis use

BW= body weight. PT=physiotherapy. SL=single leg. FC=forearm crutches. HEP=home exercise
program. GAS/SAG=order of gait when training stairs: good-affected-stick (up) then stick-affectedgood (down).

Phase one, Exposure. The goal of this phase is to expose patients to each of
the categories of rehabilitation: physiotherapy, prosthetics, hands-on treatment,
exercises, and self-care. Some patients have never had physiotherapy, and those
who have, may have not had it for an extended period or may have been exposed to
varying levels or have different expectations. It is important for the patient and
therapist to become familiar with one another, to build trust and understand the
patient’s abilities and limitations. This is similar to the patient’s relationship with their
prosthetist. The physiotherapist must expose the patient to skills and techniques
such as axial loading, joint-mobilising exercises, and self-care strategies. Many
patients have developed joint contractures, and these must be reduced as much as
possible; for example, hip flexion contracture is the most common, and lying prone is
a simple and effective strategy for patients to reduce that contracture gradually. One
critical decision that must be made by the surgeon is whether a patient is to be on
the Fast or Slow progression protocol. This is based on the overall health and fitness
of the patient, and involves assessment of the patient’s muscular strength, physical
stamina to participate in physiotherapy, and, perhaps most importantly, the bone
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quality at the time of surgery. Avoiding significant setbacks such as periprosthetic
fracture or implant pull-out is absolutely critical to the ultimate success or failure of
the surgical procedure.

Phase 2, Dependence. When the patient has acclimated to the goals of the
Exposure phase, they are ready to do early activities, but remain dependent on the
prosthetist and physiotherapist. Early fitting or sizing for a lightweight temporary
prosthesis can occur. The patient can walk, but only under the highly attentive
supervision of the physiotherapist, as their equilibrium is usually poor and they do
not have adequate balance skills and fall mechanisms learnt and able to be
executed. It is critical for every patient to continue with bilateral forearm crutches for
at least six weeks while their body relearns their balance, their confidence in their
gait improves, and they come to internalise this new limb. Healthy people do not
learn to ice skate in a week, and neither can people learn to walk with a new leg
immediately. It is also critical to avoid significant torsional force. While the implant is
strongly held to the bone within the first few weeks, the bone itself remains
osteopenic until it has had adequate time to remodel in response to loading. While
this exact number is not known, it almost certainly takes at least six weeks as that is
the time for early osteoclastic resorption and osteoblastic deposition for fractures.
Tubular bone is by nature most susceptible to fracture by torsion125, so two forearm
crutches or parallel bars must be used at all times. During this phase patients should
begin to develop habits of a home exercise program (HEP) which they will maintain
in a focused manner during the 3-6 months following PEPOL and then continue to
adhere to for the rest of their active lives.

Phase 3, Transition. This phase is characterised by patients transitioning to
understanding themselves in the context of their new extremity. They can begin to
explore early intimations of independence, such as identifying what fits their gait
while developing greater confidence and gaining comfort with their prosthesis fitting.
They can begin to walk with reduced supervision, still using two forearm crutches.
They can begin ramp training and start to involve the knee joint within their normal
gait cycle, something that is notoriously difficult to acquire considering they have
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often ambulated with a grossly distorted gait for many years previously. They can
start to taper their gait training if the physiotherapist feels they are able to self-coach
and guide their own development. They are still limited to wearing the prosthesis at
exercise and meals (to train sitting and standing from a chair) to prevent excessive
muscle fatigue, so they are not truly independent for an entire day at a time yet.

Phase 4, Development. As the patient develops their preferences and
routines as an osseointegrated amputee, they continue their transition from the prior
phase towards independence and decision making. Fewer prosthetist visits are
necessary as the patients become more stable in their gait and acquire functional
muscle balance. For patients that choose to use a microprocessor-controlled knee
joint, this is usually the best time to introduce it. At the prosthetist and
physiotherapist’s guidance, the patient can begin to wear the prosthesis all day long,
as they have learned how to avoid torsional forces. As variable contoured ground is
introduced, patients can rapidly progress their independence. However, bilateral
forearm crutch use still remains critical, as patients are only beginning to be
introduced to these different surfaces.

Phase 5, Maturation. At this phase the patient begins to determine and
assess their goals. They may still need additional prosthetic visits for minor
adjustments. They can begin to truly develop muscular stamina, as they have been
wearing the prosthesis nearly or indeed all day long. Now permitted to use just one
forearm crutch, they can work on balancing with a light load such as a grocery bag in
their other hand. They should be able to carefully navigate varying surfaces with
minimal supervision. Increasingly complex challenges and decision making, such as
what route to take through simulated obstacles that may exist in city walking or
country roads, are introduced commensurate with their level of skill. Safe falling
training is critical to mitigate the risk of injuries or periprosthetic fractures. They can
gradually taper their gait training sessions to one per week or fortnightly.
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Phase 6, Maintenance. The patient is now using their permanent full weight
prosthesis and wearing it nearly all day, has learned to fall safely, knows how to
navigate most surfaces and stairs, and is tapering to one cane or no assistive
device. They should now be considered capable of full ownership of their mobility
and prosthesis requirements. Just like maintaining general health, exercise and
practise are critical to maintaining the learned skills, and patients should repeat selftraining sessions regularly, and continue to safely challenge themselves to become
intimately familiar with their osseointegrated limb and how they use it in their own
daily life.
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FUTURE GOALS AND POSSIBILITIES FOR OSSEOINTEGRATION

The field of osseointegration has existed for almost 30 years and now appears to
be on the verge of greater acceptance and widespread implementation. Beyond
providing an excellent mobility solution for an expanding spectrum of long bone
amputees, some patients with a hip disarticulation, hemipelvectomy, or flail arm due
to brachial plexus avulsion have already had their mobility or quality of life improved
by relatively simple technical improvisations to the established fundamentals of
osseointegration. Amputation and osseointegration may even prove to be a favourable
alternative when compared with limb-salvage megaprosthesis for patients with
appendicular skeletal tumors or those who have debilitating chronic pain in an
extremity such as persistent complex regional pain syndrome 120. In this section I will
review the current challenges and future prospects of osseointegration limb
reconstruction for amputees.

A- Advances in Infection Prevention and Control

One of the biggest challenges to overcome before osseointegration surgery will be
considered acceptable in the wider medical community is the risk of infection, due to
the inherent nature of the surgery with an exposed implant. Almost all orthopaedic
surgeons would regard exposed metal as the sine qua non of an implant infection, yet
this is an integral part of the PEPOL strategy. Over the past two decades there have
been many advances in infection prevention and eradication from arthroplasty
implants, and similar principles can be also applied to PEPOL surgery. The following
discussion provides some of the approaches currently being investigated for future
applications in orthopaedic implants, and these provide a potential template for the
development of the next generation of osseointegration implants.

1-

Smart Implant Coating:
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New approaches to improve bone-implant integration should resolve the
fundamental dilemma of uncontrolled inflammation by precisely switching on/off periimplant inflammation. Inflammation characteristic of normal wound healing is required
at early stages but should be suppressed later for better healing and osseointegration.
A bioresponsive, endogenously triggered, smart coating material has been developed
to sequentially harness and then subsequently abolish the power of inflammation to
improve osseointegration, which represents a new strategy for designing
immunomodulatory biomaterials for tissue regeneration. “Bridge-burning” coating
material that comprises a macrophage-activating glycan covalently crosslinked by a
macrophage-eliminating bisphosphonate to titanium implant surface has been
designed. Upon implantation, the glycan instructs host macrophages to release proosteogenic cytokines (“switch-on”), promoting bone cell differentiation. Later,
increasingly mature bone cells secrete alkaline phosphatase to cleave the glycanbisphosphonate complexes from the implant, which in turn selectively kill the
proinflammatory macrophages (“switch-off”) that have completed their contribution;
hence, in the manner of “burning bridges”, and to promote healing and optimise
PEPOL

126

. Another smart biodegradable implant coating with poly (ethylene glycol)-

poly (propylene sulfide) polymer provides a controlled, "smart" local delivery of
antibiotics, that combines passive elution of antibiotic with an active-release
mechanism that "targets" bacteria and helps in decreasing the bacterial burden. This
strategy could be used to prevent postoperative implant-related infections 127.

2- Mechanical inactivation of Staphylococcus aureus and Pseudomonas
aeruginosa:

Titanium is the material of choice for the manufacture of orthopaedic and dental
implants because of its excellent corrosion resistance and proven biocompatibility. The
incidence of premature implant failure due to implant-associated infections, however,
remains a major concern for clinicians. Titanium substrata possessing micron-scale
surface architectures have been fabricated using a process of mask-less plasma
etching of bulk titanium for periods of 5, 10, 20, 30 and 40 minutes. The resultant
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surfaces were characterised using two-dimensional Fast-Fourier Transforms (2DFFT), scanning electron microscopy (SEM), and atomic force microscopy (AFM),
highlighting the formation of a two-tier pillared surface topology at the maximum etch
period. Each of the substrata were assessed for antibacterial efficiency against two
common human pathogens, Pseudomonas aeruginosa and Staphylococcus aureus
bacteria, achieving maximum antibacterial efficiencies of 87.2 ± 2% and 72.5 ± 13%,
respectively. Significantly, the formation of these three-dimensional (3D) hierarchical
features has been found to minimise the extent of attachment of Staph aureus cells,
directionally trapping the cells inside the micron size pillars with the second tier of
pillars acting to kill the cells. The results of this work shed new light on the development
of smart mechano-bactericidal surfaces based on tuning their micron-scale surface
topology, and suggest that such complex hierarchical surfaces can be particularly
effective towards inactivation of cocci bacteria, including Staph aureus 128.

3-

Biofilm eradication:

Biofilm formation is currently the single greatest challenge in the treatment of boneimplant-associated infections, resulting in tolerance to both the immune system and
most antibiotics. A synergistic photothermal/photodynamic therapy (PTT/PDT)
strategy aiming for biofilm eradication on titanium (Ti) implants, integrated with MPDA
loading with photosensitizer Indocyanine Green (ICG) by π-π stacking, has been
developed. A therapeutic system consisting of mesoporous polydopamine
nanoparticles (MPDA) to combat biofilm has been studied. MPDA has been
functionalized with RGD peptide to endow the modified Ti sample (Ti-M/I/RGD) with
enhanced cytocompatibility. More importantly, the Ti-M/I/RGD implant remarkably kills
Staph aureus biofilms with an efficiency of 95.4% in vivo upon near infrared (NIR).
After biofilm eradication, these implants still display excellent osteogenesis and
osseointegration performance. Overall, this study provides a viable PTT/PDT strategy
for the development of antibacterial Ti implants for potential orthopaedic applications
129

.
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4- Simultaneous Monitoring of Loosening and Temperature in Orthopaedic
Implants:

Implant failure can have devastating consequences on patient outcomes following
joint replacement, and the same holds true for PEPOL. Time to diagnosis affects
subsequent treatment success, but current diagnostics do not provide adequate early
warning and lack diagnostic sensitivity and specificity. An embedded ultrasound
system to monitor implant fixation and temperature as potential indicators of infection
has been studied. Requiring only two implanted components, a piezoelectric
transducer and a coil, pulse-echo responses are elicited via a three-coil inductive link.
This passive system avoids the need for batteries, energy harvesters, and
microprocessors, resulting in minimal changes to existing implant architecture. This
simple smart implant approach minimises the need to modify well-established implant
designs and could therefore enable mass-market adoption 130.

5- Realtime information on implant infection:

Millions of orthopaedic implant procedures are performed annually. Nonetheless,
15% of these implants fail, mainly due to poor osseointegration and/or bacterial
infection. Real-time monitoring of the physiological parameters at the tissue-implant
interface can reveal important information about the onset and severity of infection,
allowing for more timely intervention. Iridium oxide sensors are the most suitable of
the putative devices due to their low drift, high sensitivity, and high durability. This
information can also be transferred indirectly to an external device, such as a
smartphone or tablet, providing the potential for real-time monitoring of the local
conditions 131.

6- Adjuvant therapeutic agents - Delivery Options:
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Adjuvant therapeutic agents such as recombinant growth factors, lipid mediators,
antibiotics, antiphlogistics, and proangiogenics, as well as other promising antiresorptive and anabolic molecules may be able to contribute to improved bone healing
and osseointegration, especially when they are released in a targeted and controlled
manner during crucial bone healing phases. The development of smart biocompatible
and biostable polymers such as implant coatings, scaffolds, or particle-based
materials for drug release will be a crucial component. Innovative chemical, physical,
and biochemical approaches for controlled tailor-made degradation or the stimulusresponsive release of substances from these materials, and more, could all prove to
be advantageous 132.

7- Nanotechnology and Nanomaterials:

Nanotechnology has the potential to provide a plethora of novel tools for
applications in translational orthopaedic research and may eventually revolutionize the
biomedical fields. The demerits of the clinically available orthopaedic implants include
poor osseointegration at the tissue-implant interface, which subsequently results in
loosening due to low inadequate mechanical fixation, immunological rejection,
production of wear debris, and implant-related infections. Nanomaterials are promising
for orthopaedic applications because of their excellent tribological properties, wear and
tear resistance, sustained drug delivery, osseointegration, and tissue regeneration
capabilities 133.

8- Nanobiotechnology - Prevention and Treatment of Orthopaedic Implant
Associated Infection:

Nanobiotechnology has shown remarkable progress in recent years, particularly in
biomaterials, diagnostics, and drug delivery systems. Many of these advanced
strategies hold genuine promise for the prevention of orthopaedic implant related
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bacterial infection: novel "smart" drug delivery systems that release antibiotics locally
in response to stimuli such as pH, temperature, enzymes or antigens; implant surface
modifications on the nanoscale that inhibit bacterial adhesion and propagation at the
surgical site; biological approaches such as gene therapy to neutralize bacterial
virulence, and biomolecules to inhibit the quorum sensing adhesion of bacteria, with
disruption of biofilms 134.

B- Advances in Production and Biomaterials:

Currently, one of the major hurdles in advancing PEPOL technology for amputee
rehabilitation is the cost involved, primarily due to the less frequent use of this
technology. With the economy of scale this cost is expected to naturally reduce over
time, as the technique is more widely used. In addition, advances in 3D technology
and the development of new biomaterials can help to further offset future expenses if
implants can be printed locally at a lower unit cost. The challenge remains how to best
regulate the use of this technology in certain health care models where there is less
accountability. The following discussion elaborates on reported advances in implant
production and the future direction of biomaterials development.
1- Three-dimensional (3D) Printing:

Three-dimensional (3D) printing has transformed the way we can treat various
medical pathologies. A form of additive manufacturing, 3D printing fuses materials
together in a layer-by-layer fashion to construct a final 3D product. This technology
allows greater flexibility in the design process and enables efficient production of both
off-the-shelf and personalized medical products that accommodate patient needs
better than traditional manufacturing processes. In the field of orthopaedic surgery, 3D
printed implants and instrumentation can be used to address a variety of pathologies
that would otherwise be challenging to manage with products made from traditional
subtractive manufacturing

135,136

. There are numerous applications that add value to
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the personalised treatment of patients: advanced preoperative planning, surgeries
with specific tools for each patient, customised orthotic treatments, personalised
implants or prostheses and innovative developments in the field of bone and cartilage
tissue engineering

137

. 3D printing technology has revolutionized and gradually

transformed manufacturing across a broad spectrum of industries, including
healthcare 138.

2-

Customised Implants:

3D printing technology provides an excellent capability to manufacture customised
implants for patients. Computed tomography (CT) and magnetic resonance imaging
(MRI) help to provide images of the unique anatomy and pathology of an individual
patient, and these images are then used to generate patient-specific implants, guides,
and jigs 139.

3-

Natural Medicinal Compounds in Bone Tissue Engineering:

Natural medicinal compounds (NMCs) with osteogenic potential can be
incorporated into 3D-printed parts to improve bone formation and therefore enhance
implant performance 140.

4-

Cost Effectiveness of 3D Printing implants:

Application of three-dimensional (3D) printing facilities in orthopaedic surgery is
gaining popularity even in resource constrained countries. It is cost- and resourceefficient and assists in preoperative planning and increases the efficiency of
orthopaedic procedures. Furthermore, it improves educational training and provides
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cheaper prostheses and allows for the creation of customised implants for complex
and unusual cases

141

. In the last few years, 3D printable biomaterials have been

tremendously advantageous in the fabrication of orthopaedic implants because of its
light weight, minimum material wastage, porous structure for tissue ingrowth, as well
as providing ease in making patient-specific and complex topology implants. The
sustainability of the 3D printing technique, along with using sustainable biomaterials,
can make the development of implants simultaneously more accurate and more
biocompatible 142.

5-

Meta-biomaterials:

Meta-biomaterials are designer biomaterials with unusual and even unprecedented
properties that primarily originate from their geometrical designs at different (usually
smaller) length scales. This concept has been primarily used in the context of
orthopaedic biomaterials with the ultimate aim of improving the bone tissue
regeneration performance of implants while decreasing the risk of implant-associated
infections. At the macroscale, studies have discussed the concepts of patient-specific
implants, deployable meta-implants, and shape-morphing implants. At the microscale,
studies have discussed the concept of multi-physics meta-biomaterials while also
covering the applications of auxetic meta-biomaterials for improving the longevity of
orthopaedic implants. At the nanoscale, the different aspects of the geometrical design
of surface nanopatterns that simultaneously stimulate the osteogenic differentiation of
stem cells and are bactericidal have been developed (refs). The concept of origamibased meta-biomaterials and the applications of self-folding mechanisms in the
fabrication of meta-biomaterials have been addressed along with the evidence
regarding the superior performance of meta-biomaterials 143.

6-

Functionalization of 3D-printed titanium alloy orthopedic implants:
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Titanium alloy orthopaedic implants produced by 3D printing have been widely
used in the field of orthopaedics in recent years. They combine the dual advantages
of having a complex structure that cannot be manufactured by traditional techniques
and the excellent physical and chemical properties of titanium and its alloys. The ability
to design porous 3D-printed implants and the original modification processes for
titanium alloys provide conditions for the functionalisation of implants which can then
result in long-term stability with anti-infection or anti-tumor properties 144.

C- Advances in Designs and feedback of Prosthetics:

Traditional orthopaedic devices do not communicate with physicians or patients
post-operatively. After implantation, follow-up of traditional orthopaedic devices is
generally limited to episodic monitoring. Real-time health monitoring systems are
emerging in diverse medical fields, tracking biological and physiological signals for
direct feedback to the user.

1- SMART (sensing, measuring, and advanced reporting technology)
Implants:

SMART orthopaedic implants incorporate technology that enables automated
sensing, measuring, processing, and reporting of patient or device parameters at or
near the implant

145 146

. Sensors for next-generation smart implants will be small,

simple, robust, and inexpensive, and will necessitate little to no modification to existing
implant designs. With rapidly advancing technology, the widespread implementation
of smart implants is imminent. New sensor technology that minimises modifications to
existing implants is the key to seamlessly incorporating smart implants into daily
clinical practice 147.
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2- Technological Advances in Prosthesis Design and Rehabilitation:

Prosthetists have struggled to recreate the intuitive motor control, light touch
sensation, and proprioception of the innate limb in a manner that reflects the
complexity of its native form and function. Surgical advances such as targeted muscle
reinnervation, regenerative peripheral nerve interfaces, agonist-antagonist myoneural
interfaces, and targeted sensory reinnervation; development of technology designed
to restore sensation, such as implanted sensors and haptic devices; and evolution of
osseointegrated (bone-anchored) prostheses show great promise. Augmented and
virtual reality platforms have the potential to enhance prosthesis design, pre-prosthetic
training and incorporation to achieve the goal of multi-functional, self-identifiable,
durable, and intuitive prostheses 148.

3-Biofeedback to Improve the Performance of Myoelectric Pattern
Recognition:

Next generation prosthetics will rely extensively on myoelectric 'Pattern
Recognition' (PR) based control approaches, to improve their users' dexterity. One
major identified factor for the successful introduction of these approaches lies in the
training of amputees and in their understanding of how these prosthetics work. An
intuitive pattern similarity biofeedback mechanism can be easily used to train
amputees and allow them to optimise their muscular contractions to improve their
control performance 149.
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4- Neurophysiological Evaluation of Haptic Feedback for Myoelectric
Prostheses:

Evaluation of haptic feedback in myoelectric prostheses has been generally limited
to task performance outcomes, which, while necessary, fail to adequately capture the
extent of the mental effort of the user operating the prosthesis. Cognitive load is usually
investigated with reaction time metrics and secondary task accuracy which are indirect
and may not capture the time-varying nature of mental effort. Proposed wearable,
wireless, functional near infrared spectroscopy (fNIRS) neuroimaging has provided a
continuous direct assessment of operator mental effort during use of a prosthesis.
Haptic feedback can further improve task performance and lower the cognitive load
for prosthesis use and has demonstrated the potential for fNIRS to provide a robust
measure of cognitive effort for other human-in-the-loop systems 150.

D - Conclusions:

Osseointegration for the reconstruction of the amputated limb appears to now be
poised to follow a trajectory similar to that demonstrated by total joint arthroplasty.
After overcoming initial technical issues, arthroplasty benefitted from rapid and
simultaneous advances in material science and surgical techniques. This allowed
arthroplasty devices to gain universal acceptance and subsequently widespread
adoption globally over the past 50 years120.

I believe that the future of amputee rehabilitation is bright with the advances in
implant manufacturing, biofeedback and infection prevention. Over the past ten years,
I have contributed to many aspects relating to various breakthroughs in this
technology. First of which was the maturation of implant design. My design iterations
facilitated immediate rotational and axial stability, enabling patients to have shorter
rehabilitation time and also making the procedure feasible as a single-stage surgery.
By learning from the cementless arthroplasty experience, I managed to confidently
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decide what would be the best material for surface coating (plasma spray) and the
ideal porosity and thickness to achieve maximum osseointegration between the
implant and the bone. This helped me achieve maximum stability and optimise the
seal between the implant and bone. Both these features led to the reduction of
bacterial invasion of the implant-bone interface, which in turn reduced the chance of
bone infection. Improved understanding of how soft tissue interacts with the implant
when open to the outside environment led to the development of making the
transcutaneous surface of the implant highly polished with nanoparticle coating, to
minimise the potential friction between the soft tissue and the implant. This was a
progression from the original theory of trying to make the soft tissue heal directly to
the implant, which often led to inflammation and a potential increase in the occurrence
of soft tissue infection. The improved understanding of soft tissue repair around the
implant provided tight closure that no longer compromised the blood supply of the
muscular layers around the distal end of the implant, adding another barrier to bacterial
invasion and the bone implant interface. This technique further lowered the chance of
infection. Furthermore, the meticulous resection of subcutaneous fat without
devascularising the overlying skin during wound closure made the skin heal more
tightly onto the fascia covering the muscle layer. This led to reduced movement and
friction that also previously contributed to inflammation and infection.

Having optimised the implant design and surgical technique for transfemoral
amputees, with lower infections rate when compared to previously published data, this
led me to embark on testing this technology on trans-tibial amputees. Osseointegration
was trialed before in this cohort, but often failed. I progressed to more challenging and
uncharted territories, such as treating diabetic and dysvascular amputees, and even
expanded to other parts of the body, including trans-pelvic amputation. I went on to
further improve the implant design and modified our rehabilitation protocol in order to
tailor it for the anatomy, biology as well as physiology of this new group of amputees.

The next level to address was the “elephant in the room”, this being phantom limb
pain. I started paying more attention to the nervous tissue of the residuum and began
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performing regular targeted muscle reinnervation for two benefits. The first being for
the treatment of phantom limb pain and sensation, and secondly to provide a potential
source for signal transmission for the attachment of a myoelectrical prosthesis. In
addition, I performed cases where I connected agonist- antagonist muscles to provide
mind-controlled motorised prosthetic activation.

With the success of Percutaneous EndoProsthetic Osseointegration for Limbs
(PEPOL), new challenges have arisen. Patients have become more active and
therefore more demanding in terms of what the existing prosthetic limbs are capable
of delivering. Every prosthetic limb has a life expectancy. They are generally designed
for the activity levels of those with a skin-suspended socket (SSS) prosthesis, which
are proven to be on average much less active than PEPOL patients. This has
precipitated the need to consider developing a more robust prosthetic limb that can
endure the higher level of activity expected of the PEPOL population.

Furthermore, PEPOL amputees are often embarking on tasks that are deemed
very difficult, if not impossible, for those with a SSS prosthesis. Following PEPOL, the
positive effects of osseoperception has meant that they can more readily overcome
workplace obstacles such as ladders, scaffolding, and the like. These are obstacles
that the vast majority of SSS patients are typically unable to safely negotiate.

All these technological advances have been conducted in parallel with the
regulatory documentation I successfully obtained to use this technology in Europe and
Australia. I continue to seek regulatory approval to allow this technology to be used in
other parts of the world, including the United States of America, where I am in the
process of establishing an IDE with the FDA to allow this technology to be available to
the amputee population in the USA. Similar regulatory processes are being conducted
in other parts of the world, such as Japan, South Korea, and South America.
Ultimately, my goal is to make this technology available to the world-wide community
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of amputees, and to eventually become widely accepted as the standard of care for
all amputees.
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